Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof

By fusing the NRG-1 fragment with a HER3-specific antagonist antibody, the developed recombinant fusion protein addresses the cancer risk and pharmacokinetics issues of rhNRG-1, thereby improving its safety and efficacy in the treatment of cardiovascular and central nervous system diseases.

CN118909141APending Publication Date: 2024-11-08SALUBRIS BIOTHERAPEUTICS INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411003345.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-04-11
Filing Date
2019-04-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing recombinant human neuroregulatory protein-1 (rhNRG-1) has problems such as cancer promotion risk, gastrointestinal toxicity and unfavorable pharmacokinetics in clinical applications, which affect its efficacy and safety in the treatment of cardiovascular indications and central nervous system diseases.

Method used

To develop a recombinant fusion protein that blocks HER3 signaling by fusing an NRG-1 fragment with a HER3-specific antagonist antibody, thereby extending the molecular half-life, reducing cancer risk, and improving pharmacokinetics.

Benefits of technology

This fusion protein retains the therapeutic potential of NRG-1 in cardiomyocytes, reduces the risk of cancer promotion and gastrointestinal toxicity, and provides better pharmacokinetic properties, making the treatment of cardiovascular and central nervous system diseases safer and more effective.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909141A_ABST
    Figure CN118909141A_ABST
Patent Text Reader

Abstract

The present invention relates to human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof. The present invention relates to a recombinant fusion protein comprising a cardiac protection protein neuregulin-1 (NRG-1) fragment fused to a monoclonal antibody (mAb) backbone, and to a method of treating a disease or condition in a subject in need thereof, the methods comprise administering a therapeutically effective amount of the recombinant fusion protein or a pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention application with a filing date of April 11, 2019, a Chinese national application number of 201980025049.3, and an invention name of “Human Neuregulin-1 (NRG-1) recombinant fusion protein composition and its use method”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to and the benefit of U.S. Provisional Application No. 62 / 656,246, filed on April 11, 2018, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0004] The present application relates to a recombinant protein and its use in treating a disease or condition in a subject in need thereof. Background Art

[0005] Neuregulin (NRG; HRG), also known as glial growth factor (GGF) and new differentiation factor (NDF), is a glycoprotein with a molecular weight of 44KD. The NRG protein family has four members: NRG-1, NRG-2, NRG-3 and NRG-4. NRG (including NRG-1) plays a particularly important role in the development of the heart. As a ligand for the tyrosine kinase receptor of the ErbB family, NRG-1 directly binds to membrane-bound ErbB3 or ErbB4, thereby inducing dimerization to produce ErbB2 / ErbB4, ErbB2 / ErbB3, ErbB3 / ErbB3 and ErbB4 / ErbB4 complexes and subsequent intracellular signaling. In animal models, the expression of NRG induces paracrine signaling to promote the growth and differentiation of cardiac tissue during embryogenesis, where the absence of any one of ErbB2, ErbB4 or NRG-1 results in embryonic lethality. Furthermore, cancer therapies that block ErbB2 receptor signaling have been shown to have significant cardiotoxic side effects, demonstrating that ErbB2-mediated signaling in humans is critical not only for development but also for homeostasis of healthy cardiac tissue.

[0006] Evidence also suggests that NRG-1 signaling plays a role in the development and function of other organ systems and in the pathogenesis of human diseases including schizophrenia and head and neck cancer. There are many isoforms of NRG-1. Studies of genetically mutant mice (knockout mice) indicate that isoforms with different N-terminal regions or EGF-like domains have different functions in vivo. The present invention is based on the NRG-1 beta a2 isoform.

[0007] Endogenous NRG-1 binds to and induces signaling through both ErbB3 (HER3) and ErbB4 (HER4). Many preclinical and clinical studies have shown that NRG-1 has therapeutic potential in a variety of cardiovascular indications, primarily through its interaction with ErbB4 (HER4) expressed by cardiomyocytes. However, three key factors limit the clinical application and utility of recombinant human NRG-1 (rhNRG-1). First, NRG-1 signaling through HER3 may promote the development and / or progression of cancer, which raises obvious concerns for any application that requires long-term administration or is in the absence of serious cardiovascular (CV) risk factors. Second, excessive activation of HER3 by NRG-1 may disrupt gastrointestinal (GI) epithelial integrity and homeostasis, leading to severe GI toxicity and, therefore, loss of the therapeutic window of NRG-1. Third, both clinical-stage active protein fragments of rhNRG-1 exhibit short half-lives, indicating that onerous dosing and administration regimens may be required to achieve desired therapeutic exposure levels. Therefore, there is a need to provide NRG-1 based therapeutics that retain clinically significant therapeutic potential for various cardiovascular indications, but with lower risk of tumorigenesis or promotion of cancer progression, better GI tolerability, and more favorable pharmacokinetic (PK) profile.

[0008] The present invention meets these needs by providing a recombinant protein comprising a fusion of the active domain of rhNRG-1 with a HER3-specific antagonist antibody: HER3 signaling is blocked in a manner that mitigates the tumorigenic risk and GI toxicity of rhNRG-1, while the antibody backbone format confers the molecular half-life of a typical monoclonal antibody, thereby enabling more convenient dosing and administration of the product. Summary of the invention

[0009] In one aspect, the present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1), which is fused to the main chain of a monoclonal antibody (mAb). In a related aspect, the NRG-1 fragment is fused to the C-terminus of the antibody heavy chain via a linker. In another related aspect, NRG-1 is connected to the linker via the first (1st) amino acid on the N-terminus of NRG-1, and in one embodiment, the first amino acid is a serine (S or Ser) amino acid. In a related aspect, the fragment is an active fragment comprising the active domain of NRG-1. In another related aspect, the mAb has monospecificity for ErbB3 (HER3). In another related aspect, NRG-1 is the NRG-1β2a isoform.

[0010] In another aspect, the present invention relates to a pharmaceutical composition comprising a recombinant fusion protein and a pharmaceutically acceptable carrier, diluent or excipient, wherein the recombinant fusion protein comprises a fragment of the cardioprotective protein neuregulin-1 (NRG-1), wherein the fragment is fused to the main chain of an anti-HER3 monoclonal antibody.

[0011] In another aspect, the present invention relates to a method of treating a disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein or a pharmaceutical composition comprising the recombinant fusion protein disclosed herein.

[0012] In another aspect, the present invention relates to a method of preventing, inhibiting, arresting or delaying the onset of a cardiovascular disease or condition in a subject, the method comprising administering an effective amount of a recombinant fusion protein disclosed herein.

[0013] In another aspect, the invention relates to a method of treating a CNS-related disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein.

[0014] In another aspect, the invention relates to a method of preventing, inhibiting, arresting or delaying the onset of a CNS-related disease or condition in a subject, the method comprising administering an effective amount of a recombinant fusion protein.

[0015] In another related aspect, NRG-1 binds to ErbB4 (HER4) and induces signaling through ErbB4 (HER4). In another related aspect, the mAb inhibits NRG-1 signaling through ErbB3 (HER3).

[0016] In another aspect, the present invention relates to a kit comprising an effective amount of the recombinant fusion protein of the present invention or a pharmaceutical composition comprising the recombinant fusion protein of the present invention.

[0017] According to the following detailed examples and drawings, other features and advantages of the present invention will be apparent. However, it should be understood that although the detailed description and specific examples represent embodiments of the present invention, they are only given by way of illustration, because different changes and modifications within the spirit and scope of the present invention will be apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Various objects and advantages of the present invention and a more complete understanding will become apparent and more fully appreciated by referring to the following detailed description and appended claims when taken in conjunction with the accompanying drawings, in which:

[0019] Figure 1 The construction of expression plasmids for expressing the recombinant fusion proteins disclosed herein is shown.

[0020] Figure 2A -D shows the schematic structure of the recombinant fusion protein disclosed in this article. Figure 2A A molecular schematic diagram of the anti-HER3 mAb / NRG-1 fusion protein of the present disclosure is shown. Figure 2B Representative data generated by SDS-PAGE analysis are shown. Figure 2C Shown are the results of Western blots detected by a primary antibody specific for a 61-amino acid active fragment of NRG-1 that includes the HER3 / 4 binding domain ("NRG-1", R&D Systems, Minneapolis, MN). Figure 2D Shown are the results of Western blots detected by primary antibodies specific for IgG.

[0021] Figure 3 Binding analysis is presented, which shows that the recombinant fusion protein disclosed herein binds to the HER3 protein (curve 1, step 2) and can simultaneously bind to the anti-NRG-1 antibody (curve 1, step 3). It is noteworthy that Fc mutations are introduced into the recombinant fusion protein disclosed herein to knock out the Fc effector function of the parent antibody sequence encoding the HER3-specific antibody, which can reduce the adverse cytotoxicity to normal tissues expressing the HER3 receptor.

[0022] Figure 4A -D shows a representative graph showing the mean relative growth rate ± SEM (n=3) of different cancer cell lines treated with anti-HER3 mAb / NRG-1 fusion protein or control. Figure 4A Shown are the mean relative growth rates in the NCI-N87 gastric cancer cell line. Figure 4B Shown are the average relative growth rates in the MCF-7 breast cancer cell line. Figure 4C Shown are the average relative growth rates in the RT-112 bladder cancer cell line. Figure 4D The average relative growth rate in the T47D breast cancer cell line is shown. Compared to the control NRG-1 peptide and the GP120mAb / NRG-1 fusion protein, the recombinant fusion proteins provided herein exhibit significantly lower activity in promoting cancer cell proliferation.

[0023] Figure 5A -B demonstrates that, despite reduced cancer cell growth potential, the recombinant fusion protein provided herein fully retains the ability to induce PI3K / AKT signaling in cardiomyocytes, thereby exhibiting activity comparable to that of recombinant NRG-1 and GP120mAb / NRG-1 fusion protein. Figure 5AShown is a plot of the relative ratio of phospho-AKT (pAKT) to total AKT (tAKT) in human cardiomyocytes treated with recombinant fusion proteins of the present disclosure and controls versus antibody concentration (in nM). Figure 5B is a Western blot analysis of AKT phosphorylation in human cardiomyocytes treated with the recombinant fusion proteins of the present disclosure and controls.

[0024] Fig. 6A -C shows a direct comparison of HER2 / 4 and HER2 / 3 dimerization in the presence of the recombinant fusion proteins disclosed herein and a control. Fig. 6A The assay principle for detecting ligand-induced dimerization is shown. The PathHunter dimerization assay developed by Eurofins DiscoverX (Fremont, CA) is used to detect ligand-induced dimerization of two subunits of a receptor-dimer pair. The β-gal enzyme is split into two fragments: ProLink (PK) and enzyme receptor (EA). Cells have been engineered to co-express target protein 1 fused to the enzyme donor PK and target protein 2 fused to the enzyme receptor EA. The binding of a ligand to a target protein induces the ligand to interact with another target protein, thereby forcing the two enzyme fragments to complement each other and causing the enzyme reaction to release a chemiluminescent signal, which is detected in the form of relative fluorescence units or RFU. Figure 6B is a drawing showing that the recombinant fusion protein provided herein can induce HER2 / HER4 dimerization with potency comparable to NRG-1. Figure 6C is a drawing showing that the recombinant fusion protein provided herein is significantly less effective than NRG-1 in inducing HER2 / HER3 dimerization. These findings further confirm that the recombinant fusion protein provided herein retains the full HER2 / 4 signaling potential of NRG-1 while significantly reducing HER2 / 3 signaling induction.

[0025] Figure 7 The binding affinity of the anti-HER3 mAb / NRG-1 fusion protein of the present invention to HER3 antigens of different species (including humans, monkeys, rats and mice) is demonstrated. The equilibrium dissociation rates (KD) determined by BIAcore analysis are 3.13×10 -10 (person), 3.97×10 -10 (Monkey), 2.68×10 -9 (rat) and 2.77×10 -9 (Mouse). These data indicate that the recombinant fusion protein of the present invention has similar binding affinity to human and monkey HER3, while its affinity to rodent (rat and mouse) HER3 is about one order of magnitude lower.

[0026] Figure 8is a graph showing the effect of the recombinant fusion protein on ejection fraction (EF) in a rat model of systolic heart failure induced by coronary artery ligation.

[0027] Fig. 9 AF is a series of 6 images showing histopathological changes in myocardial structure in a rat model of systolic heart failure induced by coronary artery ligation. Heart tissues near the surgical site were collected and fixed in 4% formaldehyde, and then paraffin sections were prepared and stained with H&E. Fig. 9 A shows heart tissue from sham-operated control rats. Fig. 9 B shows heart tissue from systolic heart failure model rats treated with vehicle control. Fig. 9 C shows heart tissue from systolic heart failure model rats treated with GP120 mAb / NRG-1 (10 mg / kg). Fig. 9 D shows heart tissue from systolic heart failure model rats treated with anti-HER3 mAb / NRG-1 (1 mg / kg). Fig. 9 E shows heart tissue from systolic heart failure model rats treated with anti-HER3 mAb / NRG-1 (3 mg / kg). Fig. 9 F shows heart tissue from systolic heart failure model rats treated with anti-HER3 mAb / NRG-1 (10 mg / kg).

[0028] Fig.10 is a graph showing the evaluation of in vivo anti-tumor activity using a subcutaneous FaDu cancer xenograft model in NOD / SCID mice.

[0029] Fig.11 is a graph showing the changes in body weight of tumor-bearing mice treated with the recombinant fusion protein of the present disclosure and controls.

[0030] Fig.12 is a graphical representation showing the pharmacokinetic profile of the recombinant fusion protein in cynomolgus monkeys (macaques). DETAILED DESCRIPTION

[0031] The present invention uses recombinant fusion proteins comprising a monoclonal antibody fused to an active fragment of a neuregulin-1 protein isoform for a variety of cardiovascular and central nervous system (CNS) indications.

[0032] definition

[0033] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0034] For the purpose of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural, and vice versa. If any definition set forth below conflicts with any document incorporated herein by reference, the definition set forth below shall prevail.

[0035] "Neuregulin or neuregulin analogs" are molecules that can activate ErbB2 / ErbB4 or ErbB2 / ErbB3 heterodimeric protein tyrosine kinases, such as all neuregulin isoforms, individual neuregulin EGF domains, neuregulin mutants, and any kind of neuregulin-like gene products that also activate the above receptors. Preferred "neuregulins" for use in the present invention are polypeptide fragments of the human neuregulin 1β2 isoform containing an EGF-like domain and a receptor binding domain. In one embodiment, the neuregulin fragment is an active fragment. Neuregulin-1 (NRG-1) and its isoforms are also known in the art as neuregulin 1 (NRG1), glial growth factor (GGF), heregulin (HGL), HRG, new differentiation factor (NDF), ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, and NRG1 intron transcript 2 (NRG1-IT2).

[0036] The terms "ErbB3", "ErbB3 (HER3)", "HER3" refer to the same protein (or when referred to, the same gene) and are used interchangeably herein. In some embodiments, the recombinant fusion comprises a monoclonal antibody portion that is specific for ErbB3. ErbB3 (erb-b2 receptor tyrosine kinase 3) is also known in the art as FERLK, LCCS2, ErbB-3, c-erbB3, erbB3-S, MDA-BF-1, c-erbB-3, p180-ErbB3, p45-sErbB3, and p85-sErbB3.

[0037] In one embodiment, the terms "ErbB4", "ErbB4 (HER4)", "HER4" refer to the same protein (or the same gene when referred to) and are used interchangeably herein. ErbB4 (erb-b2 receptor tyrosine kinase 4) is also known in the art as ALS19 and p180erbB4.

[0038] In one embodiment, the terms "ErbB2", "ErbB2 (HER2)", "HER2" refer to the same protein (or the same gene when referred to) and are used interchangeably herein. ErbB2 (erb-b2 receptor tyrosine kinase 2) is also known in the art as NEU, NGL, TKR1, CD340, HER-2, MLN 19 and HER-2 / neu.

[0039] As used herein, the term "active" refers to a fragment having biological activity or biological function. In some embodiments, the activity is equal to or close to the activity of the wild-type protein.

[0040] The term "subject" as used herein includes, but is not limited to, mammals, including, for example, humans, non-human primates (e.g., monkeys), mice, pigs, cows, goats, rabbits, rats, guinea pigs, hamsters, horses, monkeys, sheep, or other non-human mammals; non-mammals, including, for example, non-mammalian vertebrates, such as birds (e.g., chickens or ducks) or fish; and non-mammalian invertebrates. In some embodiments, the methods and compositions of the present invention are used to treat (prophylactically and / or therapeutically) non-human animals. The term "subject" may also refer to a patient, i.e., an individual awaiting or receiving medical care.

[0041] The term "pharmaceutical composition" herein means a composition suitable for use as a pharmaceutical in a subject including an animal or a human. A pharmaceutical composition generally includes an effective amount of an active agent (e.g., a recombinant fusion protein of the present invention) and a pharmaceutically acceptable carrier, diluent or excipient (e.g., a buffer, an adjuvant, etc.).

[0042] The term "effective amount" means a dosage or amount sufficient to produce a desired result. The desired result may include an objective or subjective improvement in the recipient of the dose or amount (e.g., long-term survival, reduction in the number and / or size of tumors, effective prevention of a disease state, etc.).

[0043] "Prophylactic treatment" is a treatment applied to a subject who does not show signs or symptoms of a disease, condition or medical condition, or only shows early signs or symptoms of a disease, condition or condition, so that treatment is applied in order to reduce, prevent or reduce the risk of suffering from a disease, condition or medical condition. Prophylactic treatment is used as a preventive treatment for a disease or condition. "Prophylactic activity" is the activity of an agent such as a recombinant fusion protein of the present invention or its composition that reduces, prevents or reduces the risk of a subject suffering from a condition, disease or condition when applied to a subject who does not show signs or symptoms of a condition, disease or condition (or only shows early signs or symptoms of a condition, disease or condition). "Preventively useful" agents or compounds (e.g., recombinant fusion proteins of the present invention) refer to agents or compounds that can be used to reduce, prevent, treat or reduce the development of a condition, disease or condition.

[0044] "Therapeutic treatment" is a treatment administered to a subject who exhibits symptoms or signs of a condition, disease, or disorder, wherein the treatment is administered to the subject in order to reduce or eliminate the signs or symptoms of the condition, disease, or disorder. "Therapeutic activity" is the activity of an agent of the recombinant fusion protein of the present invention or a composition thereof that eliminates or reduces the signs or symptoms of a condition, disease, or disorder when the agent is administered to a subject suffering from such signs or symptoms. A "therapeutically useful" agent or compound (e.g., a recombinant fusion protein of the present invention) indicates that the agent or compound can be used to reduce, treat, or eliminate such signs or symptoms of a condition, disease, or disorder.

[0045] Unless otherwise indicated, the term "treating cancer" as used herein refers to partially or completely reversing, alleviating, inhibiting or preventing the progression of tumor growth, tumor metastasis or other carcinogenic or neoplastic cells in a subject. Unless otherwise indicated, the term "treatment" as used herein refers to the act of treating.

[0046] Unless otherwise indicated, the term "treating cardiovascular disease" as used herein refers to partially or completely preventing, inhibiting, preventing, delaying, reversing or alleviating the onset of a subject's cardiovascular disease or condition or the progression of a subject's pre-existing cardiovascular disease or condition or its symptoms. Non-limiting examples of cardiovascular diseases that can be treated by the methods of the present disclosure include chronic heart failure / congestive heart failure (CHF), acute heart failure / myocardial infarction (MI), left ventricular systolic dysfunction, reperfusion injury associated with MI, chemotherapy-induced cardiotoxicity (adult or pediatric), radiation-induced cardiotoxicity, and adjuncts to surgical interventions for congenital heart disease in children. Non-limiting examples of symptoms of cardiovascular disease include shortness of breath, cough, rapid weight gain, swelling of the legs, ankles and abdomen, dizziness, fatigue, weakness, lightheadedness, chest pain, fainting (syncope), tachycardia and bradycardia. Methods for determining the progression of cardiovascular disease and the efficacy of treatment will be apparent to those of ordinary skill in the art. For example, the progression of various cardiovascular diseases can be determined by ejection fraction, electrocardiogram (ECG), Holter monitoring, echocardiogram, stress testing, cardiac catheterization, cardiac computed tomography (CT) scan, and cardiac magnetic resonance imaging (MRI).

[0047] Unless otherwise indicated, the term "treating central nervous system (CNS) related diseases" as used herein refers to a method of partially or completely preventing, inhibiting, preventing, delaying, reversing or alleviating the onset of a CNS related disease or condition of a subject. The term "treating CNS related diseases" may also mean reversing, slowing down or otherwise alleviating a pre-existing CNS related disease or condition or its symptoms. Exemplary but non-limiting examples of CNS related diseases or conditions that can be treated with the methods of the present disclosure include amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Bell's palsy, epilepsy and seizures, Guillain-Barre syndrome, stroke, traumatic brain injury, multiple sclerosis or a combination. Treating CNS related diseases can improve or prevent symptoms such as tremor, bradykinesia, stiff muscles, loss of balance, impaired posture, speech changes, loss of motor control, paralysis, dysphagia, muscle spasms, seizures, memory loss and confusion.

[0048] In the context of two or more nucleic acid or polypeptide sequences, the term "identical" or "percent identity" refers to two or more sequences or subsequences that are identical or have a specified percentage of identical nucleotides or amino acid residues when compared and aligned for maximum correspondence. In order to determine the percent identity, the sequences are aligned for the purpose of optimal comparison (e.g., a vacancy can be introduced in a first amino acid sequence or nucleic acid sequence to optimally align with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When the position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = the number of identical positions / the total number of positions (e.g., overlapping positions) × 100). In some embodiments, the two sequences are the same length.

[0049] In the context of two nucleic acids or polypeptides, the term "substantially identical" means that two or more sequences or subsequences are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical (e.g., as determined using one of the methods described below).

[0050] As used herein, the terms "bind", "binds specifically to", or "has specificity for..." refer to a measurable and reproducible interaction of binding between a target and an antibody, such as determining the presence or absence of a target in the presence of a heterogeneous population of molecules comprising biomolecules. For example, an antibody that specifically binds to a target (which may be an epitope) is an antibody that binds to this target with greater affinity, activity, ease, and / or longer duration than it binds to other targets. In one embodiment, the extent to which an antibody binds to an unrelated target is less than about 10% of the extent to which the antibody binds to the target as measured, for example, by radioimmunoassay (RIA). In certain embodiments, the dissociation constant (Kd) of an antibody that specifically binds to a target is <1 μM, <100 nM, <10 nM, <1 nM, or <0.1 nM.

[0051] In certain embodiments, the antibody specifically binds to an epitope on a protein that is conserved among proteins from different species. In another embodiment, specific binding may include but does not require exclusive binding.

[0052] As used in this specification, the singular forms "a / an", "the" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a neuregulin" or "a neuregulin peptide" includes mixtures of such neuregulins, neuregulin isoforms and / or neuregulin-like polypeptides. Reference to "a formulation" or "a method" includes one or more formulations, methods and / or steps of the type described herein and / or which will become apparent to one of skill in the art upon reading this disclosure.

[0053] The term "polypeptide" refers to a polymer of amino acids and their equivalents, rather than to a specific length of the product; therefore, "peptide" and "protein" are included within the definition of polypeptide. Also included within the definition of polypeptide is an "antibody" as defined herein. A "polypeptide region" refers to a segment of a polypeptide that may contain, for example, one or more domains or motifs (e.g., a polypeptide region of an antibody may contain, for example, one or more complementarity determining regions (CDRs)). The term "fragment" refers to a portion of a polypeptide that preferably has at least 20 consecutive or at least 50 consecutive amino acids of a polypeptide.

[0054] Unless the context indicates otherwise, a "derivative" is a polypeptide or fragment thereof having one or more non-conservative or conservative amino acid substitutions relative to a second polypeptide (also referred to as a "variant"); or a polypeptide or fragment thereof modified by covalent attachment to a second molecule, such as by attachment to a heterologous polypeptide, or by glycosylation, acetylation, phosphorylation, etc. The definition of "derivative" further includes, for example, polypeptides containing analogs of one or more amino acids (e.g., non-natural amino acids, etc.), polypeptides with unsubstituted attachments, and other modifications known in the art (natural and non-naturally occurring).

[0055] An "isolated" polypeptide is one that has been identified, separated and / or recovered from components of its natural environment. Contaminant components in its natural environment are materials that would interfere with the diagnostic or therapeutic use of the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. An isolated polypeptide comprises an isolated antibody or fragment or derivative thereof.

[0056] As used herein, the term "about" means plus or minus 5%, or in another embodiment plus or minus 10%, or in another embodiment plus or minus 15%, or in another embodiment plus or minus 20% in quantitative terms.

[0057] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present disclosure, preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of disclosing and describing the materials cited in conjunction with the references.

[0058] Recombinant Fusion Proteins – Antibodies

[0059] The present invention uses recombinant fusion proteins comprising monoclonal antibodies fused to fragments of neuregulin-1 protein isoforms for a variety of cardiovascular and neurological indications. In typical embodiments, the antibody is specific for ERBB3 (HER3).

[0060] As used herein, "antibody" refers to a protein comprising one or more polypeptides encoded substantially or in part by immunoglobulin genes or fragments of immunoglobulin genes. Recognized immunoglobulin genes include κ, λ, α, γ, δ, ε and μ constant region genes, as well as numerous immunoglobulin variable region genes. Light chains are classified as κ or λ. Heavy chains are classified as γ, μ, α, δ or ε, which in turn define immunoglobulin classes IgG, IgM, IgA, IgD and IgE, respectively. Typical immunoglobulin (e.g., antibody) structural units include tetramers. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having a "light" chain (about 25 kD) and a "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light chains and heavy chains, respectively.

[0061] Antibodies exist in the form of complete immunoglobulins, or in the form of many fully characterized fragments produced by the digestion of various peptidases. Therefore, for example, pepsin digests the antibody under the disulfide bond in the hinge region to produce Fab dimer F (ab ') 2, which itself is a light chain connected to VH-CH1 by a disulfide bond. F (ab ') 2 can be reduced under mild conditions to break the disulfide bond in the hinge region, thereby converting the F (ab ') 2 dimer into a Fab ' monomer. Fab ' monomer is essentially a Fab with a hinge region part (for a more detailed description of other antibody fragments, see " Fundamental Immunology ", WE Paul edited, Raven Press, New York (Raven Press, New York) (1999)). Although various antibody fragments are defined according to the digestion of complete antibodies, it will be appreciated by those skilled in the art that such Fab ' fragments can be synthesized de novo by chemistry or by a recombinant DNA method. Therefore, as used herein, the term antibody also includes antibody fragments produced by modifying the entire antibody or synthesized de novo by a recombinant DNA method. Antibodies include single chain antibodies, including single chain Fv (sFv or scFv) antibodies, in which the variable heavy chain and variable light chain are linked together (directly or through a peptide linker) to form a continuous polypeptide. Antibodies include single domain antibodies, which include antibody fragments consisting of a single monomeric variable antibody domain that can selectively bind to an antigen domain. Exemplary single domain antibodies include VHH fragments originally isolated from camelids.

[0062] The antibody domain of the fusion protein optionally includes all or part of an immunoglobulin molecule, and optionally contains all or part of an immunoglobulin variable region (i.e., a region specific for a disease-associated antigen), and optionally includes one or more regions encoded by V genes and / or D genes and / or J genes.

[0063] As described above (see above definition), depending on the specific requirements of the embodiment, the antibody used herein optionally includes F (ab) 2, F (ab ') 2, Fab, Fab ', scFv, single domain antibodies, etc. Some embodiments utilize fusion proteins including IgG domains. However, other embodiments include alternative immunoglobulins such as IgM, IgA, IgD and IgE. In addition, all possible isotypes of various immunoglobulins are also included in the current embodiment. Therefore, IgG1, IgG2, IgG3, etc. are all possible molecules in the antibody domain of the antibody-immunostimulatory fusion protein used in the present invention. In addition to selecting the type of immunoglobulin and isotype, different embodiments of the present invention include various hinge regions (or their functional equivalents). Such hinge regions provide flexibility between different domains of antibody-immunostimulatory fusion protein. See, e.g., Penichet et al., 2001 “Antibody-cytokine fusion proteins for the therapy of cancer,” J Immunol Methods 248:91-101.

[0064] In some embodiments, the mAb included in the recombinant fusion protein of the invention is monospecific for ErbB3 (HER3).

[0065] Human HER3 (ErbB-3, ERBB3, c-erbB-3, c-erbB3, receptor tyrosine protein kinase erbB-3) encodes a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases that also includes HER1 (also known as EGFR), HER2 and HER4 (Kraus, MH et al., Proceedings of the National Academy of Sciences of the United States of America (PNAS) 86 (1989) 9193-9197; Plowman, GD et al., Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 4905-4909; Kraus, MH et al., Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 2900-2904). Like the prototype epidermal growth factor receptor, the transmembrane receptor HER3 consists of an extracellular ligand binding domain (ECD), a dimerization domain in the ECD, a transmembrane domain, an intracellular protein tyrosine kinase domain (TKD) and a C-terminal phosphorylation domain. This membrane-bound HER3 protein has a heregulin (HRG) binding domain in the extracellular domain, but no active kinase domain. Therefore, the protein can bind this ligand, but does not transmit the signal into the cell through protein phosphorylation. However, the protein does form heterodimers with other HER family members that have kinase activity. Heterodimerization leads to activation of receptor-mediated signaling pathways and transphosphorylation of its intracellular domain. Dimer formation between HER family members expands the signaling potential of HER3 and is not only a means of signal diversification, but also a means of signal amplification. For example, HER2 / HER3 heterodimers induce one of the most important mitogenic signals through the PI3K and AKT pathways in HER family members (Sliwkowski MX et al., J. Biol. Chem., 269 (1994) 14661-14665; Alimandi M et al., Oncogene 10 (1995) 1813-1821; Hellyer, NJ, J. Biol. Chem. 276 (2001) 42153-4261; Singer, E., J. Biol.).

[0066] In one embodiment, the human ERBB3 protein includes the following amino acid sequence provided in GenBank AAH02706.1 and shown in SEQ ID NO: 1:

[0067] MRANDALQVLGLLFSLARGSEVGNSQAVCPGTLNGLSVTGDAENQYQTLYKLYERCEVVMGNLEIVLTGHNADLSFLQWIREVTGYVLVAMNEFSTLPLPNLRVVRGTQVYDGKFAIFVMLNYNTNSSHALRQLRLTQLTEILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSCPPCHEVCKGRCWGPGSEDCQTLTKTICAPQCNGHCFGPNPNQCCHDECAGGCSGPQDTDCFACRHFNDSGACVPRCPQPLVYNKLTFQLEPNPHTKYQYGGVCVASCPHNFVVDQTSCVRACPPDKMEVDKNGLKMCEPCGGLCPKAF (SEQ ID NO: 1). It should be understood that the ERBB3 (HER3) sequence targeted by the antibodies of the methods and compositions of the present invention may be an isomer, homolog or variant of SEQ ID NO: 1.

[0068] In one embodiment, the mAb of the recombinant fusion protein provided herein is an anti-Her3 mAb that inhibits NRG-1 signaling through ErbB3 (HER3).

[0069] In a specific embodiment, the mAb included in the recombinant fusion protein of the present invention includes an anti-HER3 mAb. Such anti-HER3 antibodies may include, but are not limited to, the following: patritumab, seribantumab (fully human mAb), LJM716, KTN3379, AV-203, REGN1400, GSK2849330 or MM-141. Such antibodies may also be selected from the following forms, including any of a chimeric form, a bispecific form, a non-human form, a fully human form or a humanized form, as long as the form binds to human ERBB3 (HER3) and inhibits signal transduction from human ERBB3 (HER3). In some embodiments, the anti-HER3 antibody is of human origin.

[0070] In some embodiments, the term "antibody" encompasses various forms of antibody structures including but not limited to complete antibodies and antibody fragments. The antibody according to the present invention is preferably a human antibody, a humanized antibody, a chimeric antibody or another genetically engineered antibody, as long as the characteristics according to the present invention are retained. "Antibody fragment" includes a portion of a full-length antibody, preferably its variable domain or at least its antigen binding site. Examples of antibody fragments include diabodies, single-chain antibody molecules and multispecific antibodies formed by antibody fragments. ScFv antibodies are described in, for example, Huston, JS, "Methods in Enzymol." 203 (1991) 46-88. In addition, antibody fragments include single-chain polypeptides having a V H The characteristics of the domain, namely the ability to bind to V L domains assembled together, or have the ability to bind to V H The domains assemble together into a functional antigen binding site corresponding to the antigen-binding V L The characteristics of the domains, thereby providing the properties of the antibodies according to the present invention. As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to a preparation of antibody molecules of single amino acid composition.

[0071] In some embodiments, chimeric antibodies can be used for compositions and methods provided herein. In one embodiment, the term "chimeric antibody" refers to a monoclonal antibody comprising a variable region, i.e., a binding region, from a mouse and at least a portion of a constant region derived from a different source or species, and the monoclonal antibody is usually prepared by recombinant DNA technology. Chimeric antibodies comprising mouse variable regions and human constant regions are particularly preferred. Such rat / human chimeric antibodies are products of immunoglobulin genes expressed including DNA segments encoding rat immunoglobulin variable regions and DNA segments encoding human immunoglobulin constant regions. Other forms of "chimeric antibodies" encompassed by the present invention are those forms that have been modified or changed from the class or subclass of the original antibody. Such "chimeric" antibodies are also referred to as "class switching antibodies". Methods for producing chimeric antibodies relate to conventional recombinant DNA and gene transfection techniques currently well known in the art. See, for example, Morrison, SL et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855; US 5,202,238 and US 5,204,244.

[0072] In one embodiment, humanized antibodies can be used in the compositions and methods provided herein. In some embodiments, the term "humanized antibody" or "humanized form of an antibody" refers to an antibody in which the framework or "complementarity determining region" (CDR) has been modified to include an antibody having a CDR of an immunoglobulin with different specificity compared to the parent immunoglobulin. In other embodiments, the CDRs of VH and VL are grafted into the framework region of a human antibody to prepare a "humanized antibody". See, for example, Riechmann, L. et al., Nature 332 (1988) 323-327; and Neuberger, MS et al., Nature 314 (1985) 268-270. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequence can be the sequence of a naturally occurring human antibody. Human heavy and light chain variable framework regions are listed, for example, in Lefranc, M.-P., Current Protocols in Immunology (2000) - Appendix IP A.1P.1-A.1P.37 and can be obtained through IMGT (international ImMunoGeneTics information (http: / / imgt.cines.fr) or accessed via http: / / vbase.mrc-cpe.cam.ac.uk. Optionally, the framework region can be modified by further mutation. Particularly preferred CDRs correspond to CDRs representing sequences that recognize the antigen used for chimeric antibodies above. As used herein, the term "humanized antibody" also includes antibodies modified in the constant region to produce the properties of the present invention, especially with regard to antibodies that are combined with complement component 1q (Clq) and / or Fc receptor (FcR) for example by "class switching", i.e., changes or mutations of the Fc part (e.g., from IgG1 to IgG4 and / or IgG1 / IgG4 mutations). As used herein, the term "human antibody" is intended to include antibodies with variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the art (van Dijk, MA and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that are capable of producing a complete library or selection of human antibodies when immunized in the absence of endogenous immunoglobulins. The transfer of human germline immunoglobulin gene arrays in such germline mutant mice will result in the production of human antibodies when challenged by antigen (see, e.g., Jakobovits, A. et al., Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 2551-2555; Jakobovits, A. et al., Nature 362 (1993) 255-258; Brueggemann, MD et al., Year in Immunol. 7 (1993) 33-40). Human antibodies can also be produced in phage display libraries (Hoogenboom, HR and Winter, G., "J. Mol. Biol. 227 (1992) 381-388; Marks, JD, et al., "J. Mol. Biol. 222 (1991) 581-597). The techniques of Cole, A. et al. and Boerner, P. et al. can also be used to prepare human monoclonal antibodies (Cole, A., et al., "Monoclonal Antibodies and Cancer Therapy", Liss, AL, p. 77 (1985); and Boerner, P. et al., "J. Immunol. 147 (1991) 86-95). As already mentioned for humanized antibodies according to the present invention, the term "human antibody" as used herein also includes such antibodies modified in the constant region to produce the properties according to the present invention.

[0073] In a specific embodiment of the invention, the recombinant fusion proteins provided herein include a mAb that includes at least one mutation in the Fc domain or region.

[0074] As used herein, the term "recombinant human antibody" is intended to include all human antibodies prepared, expressed, produced or isolated by recombinant means, such as antibodies isolated from host cells, such as NS0 or CHO cells, or from transgenic animals (such as mice) for human immunoglobulin genes, or antibodies expressed using recombinant expression vectors transfected into host cells. Such recombinant human antibodies have variable regions and constant regions in rearranged form. The recombinant human antibodies according to the present invention have been subjected to somatic hypermutation in the receptor. Therefore, the amino acid sequences in the VH and VL regions of the recombinant antibodies are sequences that may not naturally exist in the human antibody germline library in vivo, although they are derived from and related to human germline VH and VL sequences.

[0075] In some embodiments, the terms "bind to human HER3", "specifically bind to human HER3" or "anti-HER3 antibody" are interchangeable and refer to an antibody that binds to human HER3 at about 4.81 x 10 at 25°C. -10 Antibodies that specifically bind to human HER3 antigen with a KD value of mol / L or lower. Binding affinity is determined at 25°C using standard binding assays such as GE Healthcare Uppsala, Sweden. Therefore, as used herein, "antibodies that bind to human HER3" refers to antibodies that bind to human HER3 at 1.0×10 -8 mol / L to 1.0×10 -13 The binding affinity is in the KD range of 1.5 mol / L, and preferably at 4.81× -10 An antibody or a portion thereof that specifically binds to a human HER3 antigen with a KD value of mol / L or less.

[0076] On the other hand, the anti-HER3 antibody included in the recombinant fusion protein disclosed herein includes a variable region heavy (VH) chain and a variable region light (VL) chain. In one embodiment, the antibody includes the corresponding VH sequence and VL sequence in SEQ ID NO: 2 and SEQ ID NO: 3; and has one or more of the following properties: inhibition of HER3 phosphorylation in tumor cells; inhibition of AKT phosphorylation in tumor cells; inhibition of signal transduction through ErbB3 (HER3); and inhibition of proliferation of tumor cells.

[0077] In one embodiment, the anti-HER3 mAb provided herein comprises the VH amino acid sequence shown in SEQ ID NO: 2:

[0078] Heavy Chain:

[0079]

[0080] In one embodiment, the anti-HER3 mAb provided herein comprises the VL amino acid sequence of SEQ ID NO: 3:

[0081] Light chain:

[0082]

[0083] In one embodiment, the anti-HER3 antibody of the present invention comprises at least one mutation in the Fc region. In another embodiment, the mature anti-HER3 antibody of the present invention (i.e., lacking a signal peptide) comprises at least one mutation in amino acids 234, 239, 434, or a combination thereof, wherein in other embodiments, the amino acid mutation comprises at least one of the following substitution mutations: L234F, S239A, N434A, or a combination thereof. In another embodiment, the mutation of amino acids 234 and / or 239 knocks out the effector function of the anti-HER3 antibody. In another embodiment, the mutation of amino acid 434 prolongs the half-life of the antibody in a subject.

[0084] In some embodiments, one or more mutations in the Fc region reduce effector function. In some embodiments, the reduced effector function includes a reduced affinity of the anti-HER3 antibody for one or more Fc receptors. FcR can be FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa (158F), FcγRIIIa (158V) and C1q. In some embodiments, the reduced affinity includes an increase in the dissociation constant by about 1 order of magnitude or greater. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody for FcγRI of the fusion protein including the anti-HER3 antibody from 2.81×10 -9 M increases to 1.03×10 -8 M. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody comprising the fusion protein of the anti-HER3 antibody against FcγRIIa from 3.95×10 -7 M increases to 1.35×10 -6 M. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody comprising the fusion protein of the anti-HER3 antibody against FcγRIIb from 1.03×10 -7 M increases to 1.52×10 -6M. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody comprising the fusion protein of the anti-HER3 antibody against FcγRIIIa(158F) from 6.37×10 -8 M increases to 1.18×10 -7 M. In some embodiments, the introduction of one or more Fc mutations increases the KD of the anti-HER3 antibody comprising the fusion protein of the anti-HER3 antibody against FcγRIIIa (158V) from 3.41×10 -8 M increases to 9.10×10 -8 M.

[0085] In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the antibody is greater than or equal to 1.03×10 -8 The equilibrium dissociation constant (KD) of M binds to FcγRI. In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the antibody comprises one or more Fc mutations and binds to FcγRI at a KD greater than or equal to 1.35×10 -6 In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the antibody comprises one or more Fc mutations and has a KD of greater than or equal to 1.5×10 -6 In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the antibody comprises one or more Fc mutations and has a KD greater than or equal to 1.18×10 -7 In some embodiments, the anti-HER3 antibody or recombinant fusion protein comprising the antibody comprises one or more Fc mutations and has a KD greater than or equal to 9.10×10 -8 The KD of M binds to FcγRIIIa (158V).

[0086] As used herein, the term "one or more antibody effector functions" refers to the functions contributed by one or more Fc regions of an Ig. Such functions can be affected by, for example, binding of one or more Fc effector regions to Fc receptors on immune cells with phagocytic or lytic activity or by binding of one or more Fc effector regions to components of a complement system.

[0087] In one embodiment, the anti-HER3 antibody does not induce antibody-dependent cellular cytotoxicity (ADCC).The term "antibody-dependent cellular cytotoxicity (ADCC)" refers to the lysis of human target cells by an antibody according to the invention in the presence of effector cells.

[0088] In one embodiment of the invention, the antibody according to the invention is glycosylated. In some embodiments, the glycosylation is N-glycosylation. In other embodiments, the glycosylation is O-glycosylation.

[0089] In the context of recombinant fusion protein provided herein and according to the present invention, the antibody included in the recombinant fusion protein can be produced by recombinant means. Such methods are well known in the prior art, and are included in protein expression in prokaryotic and eukaryotic cells, followed by separation of antibody polypeptides and usually purification to a pharmaceutically acceptable purity. For protein expression, nucleic acid encoding light chain and heavy chain or its fragment are inserted into expression vectors by standard methods. Expression is performed in suitable prokaryotic or eukaryotic host cells such as CHO cells, NSO cells, SP2 / 0 cells, HEK293 cells, COS cells, yeast or Escherichia coli cells, and antibodies are recovered from cells (from supernatant or after cell lysis). The recombinant production of antibodies is well known in the prior art and is described, for example, in the following review articles: Makrides, SC, Protein Expr. Purif. 17 (1999) 183-202; Geisse, S. et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, RJ, Mol. Biotechnol. 16 (2000) 151-161; Werner, RG, Drug Res. 48 (1998) 870-880. The antibodies may be present in the form of whole cells, cell lysates or partially purified or substantially pure. Purification is performed by standard techniques, including column chromatography and other techniques known in the art to eliminate other cellular components or other contaminants, such as other cellular nucleic acids or proteins (see Ausubel, F., et al., eds., Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987)). Expression in NSO cells is described, for example, by Barnes, LM et al., Cytotechnology 32 (2000) 109-123; Barnes, LM et al., Biotech. Bioeng. 73 (2001) 261-270. Transient expression is described, for example, by Durocher, Y. et al., Nucl. Acids. Res. 30 (2002) E9.Cloning of variable domains is described by Orlandi, R. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P. et al., Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289; Norderhaug, L. et al., J. Immunol. Methods 204 (1997) 77-87. A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J. and Christensen, K., Cytotechnology 30 (1999) 71-83 and by Schlaeger, E.-J., J. Immunol. Methods 194 (1996) 191-199. Monoclonal antibodies are suitably isolated from culture medium by conventional immunoglobulin purification procedures, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis or affinity chromatography. DNA and RNA encoding monoclonal antibodies are easily separated and sequenced using conventional procedures. Hybridoma cells can be used as the source of such DNA and RNA. After separation, the DNA can be inserted into an expression vector, which is then transfected into a host cell, such as HEK 293 cells, CHO cells or myeloma cells that do not otherwise produce immunoglobulins, to obtain the synthesis of recombinant monoclonal antibodies in host cells.

[0090] The heavy chain and light chain variable domains according to the present invention are combined with sequences of promoter, translation initiation, constant region, 3' untranslated region, polyadenylation and transcription termination to form an expression vector construct. The heavy chain expression construct and the light chain expression construct can be combined into a single vector co-transfected, continuously transfected or individually transfected into a host cell, and then the host cells are fused to form a single host cell expressing the two chains.

[0091] It is understood that the antibody is administered to a subject in a therapeutically effective amount, which is an amount of the subject compound or combination that will elicit the biological or medical response of a tissue, system, animal or human being that is being sought by the researcher, veterinarian, medical doctor or other clinician.

[0092] Recombinant fusion protein – Neuregulin

[0093] In one embodiment, the recombinant fusion protein provided herein includes a fragment of NRG-1 protein. NRG protein can bind to the ErbB4 receptor on the surface of cardiomyocytes, continuously activate the PI3K / AKT signaling pathway in the cells, and change the structure of cardiomyocytes, thereby improving the function of cardiomyocytes.

[0094] As used herein, "neuregulin" or "NRG" refers to a protein or peptide that can bind to and activate ErbB3, ErbB4, or a heterodimer or homodimer thereof, including a neuregulin isoform, a neuregulin EGF-like domain, a polypeptide including a neuregulin EGF-like domain, a neuregulin mutant or derivative, or any type of neuregulin-like gene product that can activate the above receptors. Neuregulin also includes NRG-1, NRG-2, NRG-3, and NRG-4 proteins, peptides, fragments, and compounds that have neuregulin functions. In a preferred embodiment, the neuregulin is a protein or peptide that can bind to and activate ErbB2 / ErbB4 or ErbB2 / ErbB3 heterodimers, for example but not for the purpose of limitation, the peptide of the present invention comprises a fragment of the NRG-1β2 isoform, i.e., a fragment of 177-237 amino acids, which contains an EGF-like domain having the following amino acid sequence: SHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASFYKAE ELYQ (SEQ ID NO: 4). The NRG protein of the present invention can activate the above receptors and regulate their biological functions, for example, stimulating the synthesis of acetylcholine receptors in skeletal muscle cells, promoting the differentiation and survival of cardiomyocytes and DNA synthesis. It is well known to those skilled in the art that mutation of a single amino acid in a non-critical region generally does not change the biological activity of the resulting protein or polypeptide (see, e.g., Watson et al., Molecular Biology of the Gene, 4th edition, 1987, Bejacmin / Cummings Pub.co., p. 224). The NRG protein of the present invention can be isolated from a natural source and can be modified by recombinant technology, artificial synthesis or other means.

[0095] As used herein, "epidermal growth factor-like domain" or "EGF-like domain" refers to a polypeptide fragment encoded by a neuregulin gene that binds to and activates ErbB3, ErbB4, or heterodimers or homodimers thereof (including heterodimers with ErbB2) and is structurally similar to the EGF receptor binding region described in: WO 00 / 64400, Holmes et al., Science, 256:1205-1210 (1992); U.S. Pat. Nos. 5,530,109 and 5,716,930; Hijazi et al., Int. Oncol. , 13:1061-1067 (1998); Chang et al., Nature, 387:509-512 (1997); Carraway et al., Nature, 387:512-516 (1997); Higashiyama et al., J. Biochem., 122:675-680 (1997); and WO 97 / 09425, the entire contents of which are incorporated herein by reference. In some embodiments, the EGF-like domain binds to and activates ErbB2 / ErbB4 or ErbB2 / ErbB3 heterodimers. In some embodiments, the EGF-like domain includes the amino acid sequence of the receptor binding domain of NRG-1. In some embodiments, the EGF-like domain refers to amino acid residues 177-226, 177-237, or 177-240 of NRG-1. In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of neuregulin-2 (NRG-2, also known in the art as DON1, HRG2, and NTAK). In certain embodiments, the EGF-like domain of NRG-2 comprises the sequence of HARKCNETAKSYCVNGGVCYYIEGINQLSCKCPNGFFGQRCL (SEQ ID NO: 15). In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of neuregulin 3 (NRG-3, also known in the art as HRG3 and pro-NRG3). In certain embodiments, the EGF-like domain of NRG-3 comprises the sequence of HFKPCRDKDLAYCLNDGECFVIETLTGSHKHCRCKEGYQGVRCD (SEQ ID NO: 16). In certain embodiments, the EGF-like domain comprises the amino acid sequence of the receptor binding domain of neuregulin 4 (NRG-4, also known in the art as HER4). In certain embodiments, the EGF-like domain of NRG-4 comprises the sequence of HEEPCGPSHKSFCLNGGLCYVIPTIPSPFCRCVENYTGARCE (SEQ ID NO: 17).In certain embodiments, the EGF-like domain comprises the amino acid sequence of AlaGlu Lys Glu Lys Thr Phe Cys Val Asn Gly Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro (SEQ ID NO: 18) as described in U.S. Pat. No. 5,834,229.

[0096] In one embodiment, the NRG-1 protein provided in the recombinant fusion protein disclosed herein is the NRG-1 β2a isoform.

[0097] In some embodiments, the active NRG-1 fragment includes an ERBB3 / 4 binding domain. In another related embodiment, NRG-1 binds to ErbB4 (HER4) and induces signaling through ErbB4 (HER4). In other embodiments, the mAb inhibits NRG-1 signaling through ErbB3 (HER3). In some embodiments, the active protein fragment of NRG-1 includes the active domain of NRG-1.

[0098] Recombinant fusion protein – composition

[0099] In one embodiment, in the recombinant fusion protein disclosed herein, NRG-1 is fused to the C-terminus of the heavy chain of the anti-HER3 antibody using a linker. In another related aspect, NRG-1 is connected to the linker via the first (1st) amino acid on the N-terminus of NRG-1, and in one embodiment, the first amino acid is a serine (S or Ser) amino acid. The specific recombinant fusion protein for use in the present invention can be optionally obtained or produced by any method known in the art (including purchase from a commercial source). For example, a nucleic acid sequence encoding a suitable antibody framework is optionally cloned and the nucleic acid sequence is connected to a suitable vector (e.g., an expression vector for, for example, a prokaryotic or eukaryotic organism). In addition, a nucleic acid sequence encoding an NRG-1β2a isoform molecule is optionally cloned into the same vector in an appropriate orientation and position so that expression from the vector produces an antibody-NRG-1β2a isoform fusion protein. Some optional embodiments also require post-expression modifications, such as assembly of antibody subunits, etc. The techniques and skills for the above (and similar) operations are well known to those skilled in the art. Related descriptions are found in, for example, Sambrook et al., Molecular Cloning—A Laboratory Manual (2nd ed.), Vols. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989 and Molecular Biology: A Laboratory Manual, FM Ausubel et al., eds., Current Protocols, Greene Publishing Associates, Inc., and John Wiley & Sons, Inc., joint venture (1999 supplement). In some alternative embodiments, the antibody domains and NRG-1β2a isoforms are assembled after expression, for example, by chemical means. In one embodiment, the invention provides a composition, for example, a pharmaceutical composition comprising a recombinant fusion protein of the invention.

[0100] In one embodiment, the recombinant fusion protein promotes cardiomyocyte proliferation, differentiation and survival. In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of cardiac tissue. In one embodiment, the recombinant fusion protein promotes cardiomyocyte proliferation, differentiation and survival without promoting cancer and / or tumor growth. In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of cardiac tissue without promoting cancer or tumor growth.

[0101] In one embodiment, the cancer is adrenocortical carcinoma, AIDS-related cancer, AIDS-related lymphoma, anal cancer, anorectal cancer, anal canal cancer, appendix cancer, childhood cerebellar astrocytoma, childhood brain astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary tract cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, brain cancer / malignant glioma. Gliomas, ependymomas, medulloblastomas, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic gliomas, breast cancer, bronchial adenoma / carcinoid, carcinoid tumors, gastrointestinal tract, nervous system cancer, nervous system lymphoma, central nervous system cancer, central nervous system lymphoma, cervical cancer, childhood cancer, chronic lymphocytic leukemia, chronic myeloproliferative disease, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, lymphoid tumors, fungal diseases, Seziary syndrome Syndrome), endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric (gastric, stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor glioma, head and neck cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, eye cancer, islet cell tumor (endocrine pancreas), Kaposi's sarcoma, kidney cancercancer), renal cancer, kidney cancer, laryngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, lip and oral cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, Clostridium difficile macroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, Merkel cell carcinoma, malignant mesothelioma, mesothelioma, metastatic squamous neck cancer, oral cancer, tongue cancer, multiple endocrine neoplasms syndrome, mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative diseases, chronic myeloid leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative diseases, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity cancer, oropharyngeal cancer, ovarian cancer, ovarian epithelial cancer, ovarian low Tumors of high malignant potential, pancreatic cancer, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, blastoblastoma and supratentorial primitive neuroepithelioma tumors, plasma cell neoplasm / multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter cancer, transitional cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Ewing's sarcoma family, Kaposi's sarcoma, soft tissue sarcoma, epithelioid sarcoma , uterine cancer, uterine sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), Merkel cell skin cancer, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, gastric cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, laryngeal cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the urinary organs such as the renal pelvis and ureter, gestational trophoblastic tumor, urethral cancer, endometrial uterine cancer, uterine sarcoma, uterine body cancer, vaginal cancer, vulvar cancer or Wilm's tumor.

[0102] In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of central nervous system (CNS) cells. In another embodiment, the recombinant fusion protein promotes the proliferation, differentiation and survival of central nervous system (CNS) cells without promoting cancer and / or tumor growth. In another embodiment, the ability of the recombinant fusion protein to induce antibody-dependent cellular cytotoxicity (ADCC) is reduced.

[0103] In some embodiments, the recombinant fusion protein promotes HER2 / 4 signaling over HER2 / 3 signaling relative to the signal induction potential of recombinant NRG-1.

[0104] In a specific embodiment of the invention, the recombinant fusion protein comprises an anti-HER3 mAb fused to or operably linked to the C-terminus of the antibody heavy chain via a GGGGSGGGGS (G4S) linker SEQ (SEQ ID NO: 5) linked to the NRG-1β2a isoform of SEQ ID NO: 4. In some embodiments, one or more copies of the linker may be used. In other embodiments, 2, 3, 4, or 5 copies of the G4S linker or any other linker known in the art suitable for the compositions disclosed herein may be used herein.

[0105] The term "linker" is recognized in the art and refers to a molecule (including but not limited to unmodified or modified nucleic acids or amino acids) or a group of molecules (e.g., 2 or more, e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more) that connects two compounds, such as two polypeptides. A linker can consist of a single linker molecule, or can include a linker molecule and at least one spacer molecule intended to separate the linker molecule and the compound by a specific distance.

[0106] A nucleic acid sequence is "operably linked" when it is in a functional relationship with another nucleic acid sequence. For example, a nucleic acid presequence or secretory leader is operably linked to a nucleic acid encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of a polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned to facilitate translation. Generally, "operably linked" means that the nucleic acid sequences being linked are continuous, and in the case of a secretory leader, continuous and in reading frame. However, enhancers are optionally continuous. Connection can be accomplished, for example, by connection at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide linkers, linkers, or other methods known in the art can be used. In another embodiment, "operably linked" also refers to the functional pairing of unique amino acid sequences, peptides, or proteins, such as the pairing of antibodies and NRG-1 fragments also through the linker sequences described herein.

[0107] In another embodiment, the recombinant fusion protein provided herein comprises an anti-HER3 mAb heavy chain encoded by SEQ ID NO: 6:

[0108]

[0109] In one embodiment, the recombinant fusion protein provided herein includes the heavy chain of anti-HER3 mAb. In another embodiment, the anti-HER3 mAb heavy chain is encoded by SEQ ID NO:7:

[0110]

[0111] In one embodiment, the recombinant fusion protein provided herein includes the light chain sequence of anti-HER3mAb. In another embodiment, the light chain sequence is encoded by (SEQ ID NO:8):

[0112] (SEQ ID NO:8). In one embodiment, SEQ ID NO:8 is also referred to as "PAL".

[0113] In one embodiment, the heavy chain of the anti-HER3 antibody included in the recombinant fusion protein provided herein includes the following amino acid sequence:

[0114] (SEQ ID NO:9).

[0115] In one embodiment, the heavy chain of the anti-HER3 antibody included in the recombinant fusion protein provided herein includes the following amino acid sequence:

[0116] (SEQ ID NO: 10).

[0117] In one embodiment, the anti-HER3 mAb heavy chain sequence includes a signal peptide sequence. In another embodiment, the anti-HER3 mAb heavy chain signal peptide sequence includes an amino acid sequence of MEFGLSWVFLVAIIKGVQC (SEQ ID NO: 11).

[0118] In one embodiment, the light chain of the anti-HER3 antibody included in the recombinant fusion protein includes the following amino acid sequence:

[0119] MVLQTQVFISLLLWISGAYGDIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPR TFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:12).

[0120] In one embodiment, the anti-HER3 mAb light chain sequence includes a signal peptide sequence. In another embodiment, the anti-HER3 mAb light chain signal peptide sequence includes an amino acid sequence of MVLQTQVFISLLLWISGAYG (SEQ ID NO: 13). In one embodiment, a mature polypeptide such as an antibody heavy chain or light chain amino acid sequence disclosed herein lacks a signal peptide.

[0121] In one embodiment, the recombinant fusion protein comprises the following amino acid sequence:

[0122] Heavy chain

[0123]

[0124] (SEQ ID NO: 14, wherein bold italics indicate a linker, and bold indicates an NRG-1 fragment); and

[0125] Light chain

[0126] DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEI KRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:3).

[0127] In one embodiment, each of the heavy chain sequence and the light chain sequence in the mature recombinant fusion protein lacks a signal peptide amino acid sequence.

[0128] In a specific embodiment of the invention, the heavy chain of the anti-HER3 antibody provided herein is fused to the NRG-1β2a isoform provided herein via a C-terminal linker sequence. In another embodiment, the C-terminus of the antibody heavy chain includes the Fc domain of the antibody.

[0129] In some embodiments, provided are pharmaceutical compositions comprising a recombinant fusion protein disclosed herein formulated together with a pharmaceutical carrier.

[0130] In some embodiments, the anti-HER3 antibody and NRG-1 fragment described herein are recombinantly or chemically fused / operably linked via a linker to form a fusion protein. "Fusion protein", "fusion polypeptide", "recombinant fusion protein" or "recombinant polypeptide" refers to a hybrid polypeptide comprising polypeptide portions from at least two different polypeptides. As defined herein, a "fusion protein" is a fusion comprising, for example, a first amino acid sequence (protein) of an NRG-1β2a isoform of the present invention connected to the C-terminus of a second amino acid sequence of a heavy chain of an antibody that specifically binds to ERBB3 (HER3) via a linker.

[0131] In one embodiment, the fusion protein is recombinantly encoded and produced. In some embodiments, the recombinant fusion protein is encoded by a nucleic acid sequence encoding an antibody of the invention operably linked to a nucleic acid sequence encoding an NRG-1 β2a isoform of the invention via a nucleic acid sequence encoding a linker.

[0132] In one embodiment, the recombinant fusion protein amino acid sequence is homologous to SEQ ID NO:14 fused to SEQ ID NO:3. The term "homology" may refer to an identity greater than 70% with a recombinant fusion protein sequence (e.g., any one of SEQ ID NOs:1-18). In another embodiment, "homology" refers to an identity greater than 72% with any one of SEQ ID NOs:1-18. In another embodiment, "homology" refers to an identity greater than 75% with any one of SEQ ID NOs:1-18. In another embodiment, "homology" refers to an identity greater than 78% with any one of SEQ ID NOs:1-18. In another embodiment, "homology" refers to an identity greater than 80% with any one of SEQ ID NOs:1-18. In another embodiment, "homology" refers to an identity greater than 82% with any one of SEQ ID NOs:1-18. In another embodiment, "homology" refers to an identity greater than 83% with any one of SEQ ID NOs:1-18. In another embodiment, "homology" refers to an identity greater than 85% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 87% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 88% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 90% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 92% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 93% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 95% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 96% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to an identity greater than 97% with any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to greater than 98% identity to any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to greater than 99% identity to any one of SEQ ID NOs: 1-18. In another embodiment, "homology" refers to 100% identity to any one of SEQ ID NOs: 1-18.

[0133] The determination of the percent identity between two sequences can be accomplished using a mathematical algorithm. A non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such algorithms are incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Molecular Biology 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program (score = 100, word length = 12) to obtain nucleotide sequences homologous to the nucleic acid encoding the protein of interest. BLAST protein searches can be performed with the XBLAST program (score = 50, word length = 3) to obtain amino acid sequences homologous to the protein of interest. In order to obtain a gap comparison for comparison purposes, it is possible to utilize the gapped BLAST described in Altschul et al., 1997, Nucleic Acids Research 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterative search for a long-range relationship between detection molecules (the same). When utilizing BLAST, gapped BLAST and PSI-BLAST programs, the default parameters of each program (e.g., XBLAST and NBLAST) can be used. Another non-limiting example of a mathematical algorithm for sequence comparison is the algorithm of Myers and Miller, "Computer Applications in Biological Sciences (CABIOS)" (1989). Such algorithms are incorporated into the ALIGN program (Version 2.0), which is a part of the GCG sequence alignment software package. When utilizing the ALIGN program to compare amino acid sequences, PAM120 weight residue tables, gap length penalties of 12, and gap penalties of 4 can be used. Other algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti, 1994, Comput. Appl. Biosci. 10:3-5; and FASTA as described in Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444-8. In FASTA, ktup is a control option that sets the sensitivity and speed of the search. If ktup=2, similar regions in the two compared sequences are found by looking at pairs of aligned residues; if ktup=1, single aligned amino acids are examined. For protein sequences, ktup can be set to 2 or 1, or for DNA sequences, ktup can be set to 1 to 6. If ktup is not specified, the default value for protein is 2 and the default value for DNA is 6.Alternatively, protein sequence alignments may be performed using the CLUSTAL W algorithm as described in Higgins et al., 1996, Methods Enzymol. 266:383-402.

[0134] In some embodiments, the polynucleotides of the present invention are prepared using PCR techniques using procedures and methods known to those skilled in the art. In some embodiments, the procedure involves the connection of two different DNA sequences (see, e.g., "Molecular Biology Laboratory Manual", ed. Ausubel et al., John Wiley & Sons, 1992).

[0135] In one embodiment, the polynucleotide of the present invention is inserted into an expression vector (i.e., a nucleic acid construct) to enable expression of a recombinant polypeptide. In one embodiment, the expression vector of the present invention comprises additional sequences that make this vector suitable for replication and integration in prokaryotes. In one embodiment, the expression vector of the present invention comprises additional sequences that make this vector suitable for replication and integration in eukaryotes. In one embodiment, the expression vector of the present invention comprises a shuttle vector that makes this vector suitable for replication and integration in prokaryotes and eukaryotes. In some embodiments, the cloning vector includes transcription and translation initiation sequences (e.g., promoters, enhancers) and transcription and translation terminators (e.g., polyadenylation signals).

[0136] In one embodiment, various prokaryotic cells or eukaryotic cells can be used as host expression systems for expressing the polypeptides of the present invention. In some embodiments, these cells include but are not limited to microorganisms, such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing polypeptide coding sequences; yeast transformed with recombinant yeast expression vectors containing polypeptide coding sequences.

[0137] In some embodiments, a non-bacterial expression system (e.g., a mammalian expression system, such as CHO cells) is used to express the polypeptides of the invention. In one embodiment, the expression vector for expressing the polynucleotides of the invention in mammalian cells is a pCI-DHFR vector comprising a CMV promoter and a neomycin resistance gene.

[0138] In certain embodiments, in bacterial systems of the present invention, many expression vectors can be advantageously selected depending on the purpose of the polypeptide intended for expression. In one embodiment, a large amount of polypeptides are desired. In one embodiment, it is desired to guide the carrier of high-level expression of a protein product that may be a fusion with a hydrophobic signal sequence, and the product expressed is guided to the periplasm of the bacterium or culture medium that is easy to purify the protein product. In one embodiment, a certain fusion protein is engineered to have a specific cleavage site to help the recovery of the polypeptide. In one embodiment, the carrier suitable for such manipulation includes but is not limited to the Escherichia coli expression vector of the pET series [Studier et al., Methods in Enzymology 185:60-89 (1990)].

[0139] In one embodiment, a yeast expression system is used. In one embodiment, a number of vectors containing constitutive or inducible promoters can be used in yeast, as disclosed in U.S. Pat. No. 5,932,447. In another embodiment, a vector that promotes integration of exogenous DNA sequences into yeast chromosomes is used.

[0140] In one embodiment, the expression vector of the present invention may further comprise additional polynucleotide sequences that allow, for example, translation of several proteins from a single mRNA, such as an internal ribosome entry site (IRES) and sequences for genomic integration of the promoter-chimeric polypeptide.

[0141] In some embodiments, the expression vector of the present invention comprises elements that increase the expression of the recombinant fusion protein of the present invention. Such features include, but are not limited to, the selection of promoters and polyadenylation. In some embodiments, the polyadenylation sequence is a bovine growth hormone (BGH) polyadenylation sequence. In some embodiments, the promoter comprises a constitutively active promoter. In some embodiments, the promoter comprises a cytomegalovirus promoter (pCMV).

[0142] In some embodiments, mammalian expression vectors include, but are not limited to, pcDNA3, pcDNA3.1 (+ / -), pGL3, pZeoSV2 (+ / -), pSecTag2, pDisplay, pEF / myc / cyto, pCMV / myc / cyto, pCR3.1, pSinRep5, DH26S, DHBB, pNMT1, pNMT41, pNMT81, which are available from Invitrogen, pCI which is available from Promega, pMbac, pPbac, pBK-RSV and pBK-CMV which are available from Strategene, pTRES which is available from Clontech, and its derivatives.

[0143] In some embodiments, the present invention uses expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses. SV40 vectors include pSVT7 and pMT2. In some embodiments, vectors derived from bovine papilloma virus include pBV-1MTHA, and vectors derived from Epstein-Barr virus include pHEBO and p205. Other exemplary vectors include pMSG, pAV009 / A + 、pMTO10 / A + , pMAMneo-5, baculovirus pDSVE and any other vector that allows protein expression under the direction of the SV-40 early promoter, the SV-40 late promoter, the metallothionein promoter, the mouse mammary tumor virus promoter, the Rous sarcoma virus promoter, the polyhedrin promoter or other promoters effective for expression in eukaryotic cells.

[0144] In certain embodiments, recombinant viral vectors can be used for expressing polypeptides of the present invention in vivo, because they provide advantages such as lateral infection and targeting specificity. In one embodiment, lateral infection is inherent in the life cycle of, for example, retroviruses, and is the process in which a single infected cell produces many progeny virions that sprout and infect adjacent cells. In one embodiment, the result is that large areas are rapidly infected, wherein most of them are not initially infected by the original virus particles. In one embodiment, a viral vector that cannot spread laterally is produced. In one embodiment, if the desired purpose is to introduce only a specific gene into the target cell of a local quantity, this characteristic may be useful.

[0145] In one embodiment, various methods can be used to introduce expression vectors encoding recombinant fusion proteins of the present invention into cells. Such methods are generally described in the following: Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989, 1992); Ausubel et al., Molecular Biology Laboratory Guide, John Wiley & Sons, Baltimore, Maryland (Baltimore, Md.) (1989); Chang et al., Somatic Gene Therapy, CRC Press, Ann Arbor, Michigan (Ann Arbor, Mich.) (1995); Vega et al., Gene Targeting, CRC Press, Ann Arbor, Michigan (1995), Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Butterworths Press, Boston, Massachusetts (Boston) Mass.) (1988); and Gilboa et al. [Biotechniques 4 (6): 504-512, 1986], and include stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. In addition, for positive-negative selection methods, see U.S. Patents Nos. 5,464,764 and 5,487,992.

[0146] In some embodiments, introduction of nucleic acids via viral infection offers several advantages over other methods such as lipofection and electroporation because higher transfection efficiencies can be achieved due to viral infectivity.

[0147] In one embodiment, it should be understood that the polypeptide of the present invention can also be expressed by the nucleic acid constructs applied to individuals by any suitable mode of administration as described above (i.e., in vivo gene therapy). In one embodiment, the nucleic acid constructs are introduced into suitable cells by suitable gene delivery vectors / methods (transfection, transduction, homologous recombination, etc.) and expression systems as needed, and then the modified cells are amplified in culture and returned to the individual (i.e., ex vivo gene therapy).

[0148] It will be appreciated that, in addition to containing the necessary elements for transcription and translation of the inserted coding sequence (encoding a polypeptide), the expression constructs of the invention may also contain sequences engineered to optimize stability, production, purification, yield or activity of the expressed polypeptide.

[0149] In certain embodiments, the transformed cells are cultured under effective conditions that allow expression of a large amount of recombinant fusion proteins or polypeptides. In certain embodiments, effective culture conditions include but are not limited to effective culture medium, bioreactor, temperature, pH and oxygen conditions that allow protein production. In one embodiment, effective culture medium refers to any culture medium in which cells are cultured to produce recombinant polypeptides of the present invention. In certain embodiments, culture medium generally comprises an aqueous solution with absorbable carbon, nitrogen and phosphate sources, as well as suitable salts, minerals, metals and other nutrients such as vitamins. In certain embodiments, cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes and culture dishes. In certain embodiments, culture is carried out under temperature, pH and oxygen content that are suitable for recombinant cells. In certain embodiments, culture conditions are within the professional knowledge of those of ordinary skill in the art.

[0150] In some embodiments, depending on the vector and host system used for production, the resulting polypeptide of the invention is retained within the recombinant cell, secreted into the fermentation medium, secreted into the space between two cell membranes (such as the periplasmic space in E. coli), or retained on the outer surface of the cell or viral membrane.

[0151] In one embodiment, after a predetermined period of culturing, recovery of the recombinant polypeptide is achieved.

[0152] In one embodiment, the phrase "recovering the recombinant polypeptide" as used herein refers to collecting the entire fermentation medium containing the polypeptide, and does not necessarily imply additional steps of isolation or purification.

[0153] In one embodiment, the polypeptides of the invention are purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing, and differential solubilization.

[0154] In one embodiment, for the convenience of recovery, the expressed coding sequence can be engineered to encode the polypeptide of the present invention and the cleavable part of the fusion. In one embodiment, the fusion protein can be designed so that the polypeptide can be easily separated by affinity chromatography, for example, by fixing on a column with specificity for the cleavable part. In one embodiment, a cleavable site is engineered between the polypeptide and the cleavable part, and the polypeptide can be released from the chromatographic column by treating with a suitable enzyme or agent that specifically cuts the fusion protein at this site [e.g., see Booth et al., Immunology Express (Immunol. Lett.) 19: 65-70 (1988); and Gardella et al., Journal of Biological Chemistry 265: 15854-15859 (1990)].

[0155] In one embodiment, a polypeptide of the invention is recovered in a "substantially pure" form.

[0156] In one embodiment, the phrase "substantially pure" refers to a degree of purity that permits effective use of the protein in the applications described herein.

[0157] In one embodiment, the polypeptides of the present invention can also be synthesized using an in vitro expression system. In one embodiment, in vitro synthesis methods are well known in the art, and the components of the system are commercially available.

[0158] In some embodiments, recombinant polypeptides are synthesized and purified; their therapeutic efficacy can be assayed in vivo or in vitro.

[0159] In one embodiment, the pharmaceutical composition comprising the recombinant fusion protein of the present invention provided herein is further formulated with a pharmaceutical carrier. As used herein, a "pharmaceutical carrier" comprises any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents that are physiologically compatible. Preferably, the carrier is suitable for intravenous administration, intramuscular administration, subcutaneous administration, parenteral administration, spinal administration or epidermal administration (e.g., by injection or infusion).

[0160] Treatment

[0161] In one embodiment, the present invention provides a method of treating a disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein or a pharmaceutical composition comprising a recombinant fusion protein disclosed herein.

[0162] In one embodiment, the present invention provides a method of treating a cardiovascular disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein or a pharmaceutical composition comprising the recombinant fusion protein.

[0163] In one embodiment, the present invention provides a method for preventing, inhibiting, arresting or delaying the onset of a cardiovascular disease or condition in a subject, the method comprising administering an effective amount of the recombinant fusion protein or pharmaceutical composition described herein.

[0164] In some embodiments, cardiovascular disease includes chronic heart failure / congestive heart failure (CHF), acute heart failure / myocardial infarction (MI), left ventricular systolic dysfunction, reperfusion injury associated with MI, chemotherapy-induced cardiotoxicity (adult or pediatric), radiation-induced cardiotoxicity, adjunct to surgical intervention for pediatric congenital heart disease.

[0165] In some embodiments, chemotherapy-induced cardiotoxicity is caused by the subject receiving anthracyclines, alkylating agents, anti-microtubule agents, and antimetabolites as chemotherapy.

[0166] In some embodiments, the cardiovascular condition is due to cardiotoxicity caused by the subject receiving cancer therapy. In other embodiments, the cancer therapy is HER-2 targeted therapy. In other embodiments, HER-2 targeted therapy includes the use of trastuzumab, ado-trastuzumab, emtansine, lapatinib, neratinib and pertuzumab, any anti-HER2 antibody, any anti-HER2 agent, or a combination thereof.

[0167] In another aspect, the present invention relates to a method for inducing remodeling of sarcomere and cytoskeletal structure or cell-cell adhesion of muscle cells, the method comprising treating the cells with the recombinant fusion protein disclosed herein.

[0168] In one embodiment, the method of treatment relates to treating heart failure in a mammal due to separation of cardiomyocyte-cell adhesions and / or disorganization of sarcomere structure.

[0169] In another aspect, the present invention provides a method for preventing, treating or delaying heart failure with preserved ejection fraction in a human, the method comprising administering a pharmaceutical composition comprising the recombinant fusion protein disclosed herein.

[0170] As used herein, the term "ejection fraction" refers to the ejection fraction (EF), a measure of how much blood the left ventricle pumps out with each contraction, which is usually expressed as a percentage. For example, an ejection fraction of 50% means that 50% of the total blood volume in the left ventricle is pushed out with each heartbeat.

[0171] The present invention is directed to treating subjects suffering from, or at risk of developing, heart disease and related conditions, such as heart failure.

[0172] The term "heart failure" refers to an abnormality in cardiac function in which the heart does not pump blood at the rate required by metabolic tissues. Heart failure encompasses a variety of disease states, such as congestive heart failure, myocardial infarction, arrhythmias, familial hypertrophic cardiomyopathy, ischemic heart disease, idiopathic dilated cardiomyopathy, and myocarditis. Heart failure may be caused by any number of factors including ischemic, congenital, rheumatic, or idiopathic forms. Chronic cardiac hypertrophy is a serious disease state that is a precursor to congestive heart failure and cardiac arrest.

[0173] In one embodiment, "treatment" refers to both therapeutic treatment and preventive or preventive measures, wherein the goal is to prevent or slow down (mitigate) cardiac hypertrophy. Subjects in need of treatment include subjects who have suffered from the disease and subjects who are prone to the disease or subjects for whom the disease is to be prevented. Cardiac hypertrophy may come from any cause that responds to retinoic acid, including congenital, viral, idiopathic, cardiac nutritional or myotrophic causes, or ischemic or ischemic damage (such as myocardial infarction) caused. Typically, in order to stop or slow down the progress of hypertrophy, particularly after the occurrence of cardiac damage such as due to ischemia, treatment is performed. Preferably, in order to treat myocardial infarction, a pharmaceutical composition provided herein is administered immediately after myocardial infarction to prevent or alleviate hypertrophy.

[0174] In some embodiments, treatment of subjects with a pharmaceutical composition comprising a recombinant fusion protein provided herein can increase the average survival time of the population of treated subjects compared to a population receiving a monotherapy with a drug that is not a compound of the present disclosure or a pharmaceutically acceptable salt, solvate, analog or derivative thereof. Preferably, after treatment with the strategies, treatment modalities, methods, combinations and compositions provided herein, the average survival time increases by more than 30 days; more preferably, more than 60 days; more preferably, more than about 90 days, 120 days or 365 days; more preferably, more than 365 days. The increase in the average survival time of a population can be measured in any reproducible manner. The increase in the average survival time of a population can be measured, for example, by calculating the average survival length of a population after the start of treatment with an active compound. The increase in the average survival time of a population can also be measured, for example, by the following method: by calculating the average survival time of a population after the first round of treatment with a pharmaceutical composition disclosed herein.

[0175] In some embodiments, treatment of subjects with a pharmaceutical composition comprising a recombinant fusion protein provided herein can result in a reduced mortality rate in the treated subject population compared to a population receiving only a carrier. Treatment of cancer can result in a reduced mortality rate in the treated subject population compared to an untreated population. Treatment of cancer can result in a reduced mortality rate in the treated subject population compared to a population receiving monotherapy (the drug used is not a compound disclosed herein or a pharmaceutically acceptable salt, solvate, analog or derivative thereof). Preferably, after treatment with the strategies, treatment forms, methods, combinations and compositions provided herein, the mortality rate is reduced by more than 2%; more preferably, more than 5%; more preferably, more than 10%; and most preferably, more than 25%. The reduction in the mortality rate of the treated subject population can be measured in any reproducible manner. The reduction in the mortality rate of the population can be measured, for example, by calculating the average number of disease-related deaths in the population per unit time after the start of treatment with the active compound. The reduction in the mortality rate of the population can also be measured, for example, by the following: after completing the first round of treatment with the pharmaceutical composition disclosed herein, the average number of disease-related deaths in the population per unit time is calculated.

[0176] In one embodiment, the present invention provides a method of treating a central nervous system (CNS)-related disease or condition in a subject in need thereof, the method comprising administering a therapeutically effective amount of a recombinant fusion protein or pharmaceutical composition described herein.

[0177] In one embodiment, the present invention provides a method for preventing, inhibiting, arresting or delaying the onset of a CNS-related disease or condition in a subject, the method comprising administering an effective amount of the recombinant fusion protein or pharmaceutical composition described herein.

[0178] In some embodiments, the CNS-related disease or condition is amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Bell's palsy, epilepsy and seizures, Guillain-Barre syndrome, stroke, traumatic brain injury, multiple sclerosis, or a combination.

[0179] Administration, dosing

[0180] The composition of the present invention can be administered parenterally to a subject in need, or can be administered by a variety of methods known in the art. As will be appreciated by those skilled in the art, the route and / or mode of administration will vary depending on the desired result. In order to administer the compound of the present invention by certain routes of administration, it may be necessary to coat the compound with a material to prevent its inactivation or co-administer it with the compound. For example, the compound can be administered to a subject in a suitable carrier, such as a liposome or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutical carriers include sterile aqueous solutions or dispersions and sterile powders for the temporary preparation of sterile injection solutions or dispersions. The use of such culture media and medicaments for pharmaceutically active substances is known in the art.

[0181] In typical embodiments, the preparation for administering to a subject comprises sterile aqueous or non-aqueous solutions, suspensions and emulsions. Some embodiments comprise non-aqueous solvents, such as propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), organic esters (e.g., ethyl oleate) and other solvents known to those skilled in the art. In certain embodiments of the present invention, a physiologically acceptable carrier (or excipient) is optionally used. Such examples include, for example, saline, PBS, Ringer's solution, lactated Ringer's solution, etc. In addition, preservatives and additives are optionally added to the composition to help ensure stability and sterility. For example, antibiotics and other bactericides, antioxidants, chelating agents, etc. are optionally present in each embodiment of the composition herein.

[0182] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to modes of administration other than enteral and topical administration, usually by injection, and include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal injection and infusion.

[0183] Whichever administration route is chosen, the compound of the present invention used in an appropriate hydrated form and / or the pharmaceutical composition of the present invention can be formulated into a pharmaceutically acceptable dosage form by other conventional methods known to those skilled in the art.

[0184] The recombinant fusion protein or a pharmaceutical composition comprising the recombinant fusion protein is optionally administered to a subject in need of treatment (therapeutically or preventively) in any suitable sterile pharmaceutical carrier. The effect of such pharmaceutical carriers is to maintain the solubility and effect of the fusion protein. In some embodiments, it may be desirable to administer additional components together with the fusion protein. For example, in some treatment regimens, chemotherapeutic agents, antibiotics, additional formulations comprising the recombinant fusion protein of the present invention and one or more standard care agents, etc. are all optionally included in the composition of the present invention.

[0185] As used herein, the terms "combination therapy", "combination therapy" and "co-therapy" are used interchangeably and generally refer to a treatment regimen characterized by a recombinant fusion protein provided herein or a pharmaceutical composition comprising the recombinant fusion protein and an additional therapeutic agent. Typically, a combination therapy form is part of a specific treatment regimen intended to provide a beneficial effect of a parallel action from a combination of therapeutic agents. The beneficial effects of the combination may include, but are not limited to, a pharmacokinetic or pharmacodynamic co-action produced by a combination of therapeutic agents. The combined administration of these therapeutic agents is usually performed within a defined time period (usually minutes, hours, days or weeks, depending on the selected combination). In some embodiments, the combination therapy includes administering two or more therapeutic agents in a sequential manner, wherein each therapeutic agent is administered at different times, and administering these therapeutic agents or at least two of these therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to a subject a single dosage form of each therapeutic agent having a fixed ratio or with multiple independent dosage forms for therapeutic agents. The sequential administration of each therapeutic agent can be achieved by any appropriate approach or substantially simultaneous administration, and these approaches include but are not limited to oral routes, intravenous routes, intramuscular routes, and direct absorption by mucosal tissue. These therapeutic agents can be administered by the same approach or by different approaches. The therapeutic agent can be administered according to the same or different administration intervals. For example, the first therapeutic agent of the combination selected can be administered by intravenous injection, and the other therapeutic agents in the combination can be administered orally at the same time. Alternatively, for example, all therapeutic agents can be administered orally or all therapeutic agents can be administered by intravenous injection.

[0186] In some embodiments, the combination therapy also includes the administration of the above therapeutic agents further combined with other biologically active ingredients and non-drug therapies (e.g., surgery or radiotherapy). When the combination therapy further includes non-drug therapy, the non-drug therapy can be performed at any appropriate time, as long as a beneficial effect is achieved from the combined action of the therapeutic agent and the non-drug therapy. For example, in appropriate circumstances, when the non-drug therapy is temporarily removed from the administration of the therapeutic agent (perhaps for several days or even weeks), a beneficial effect is still achieved.

[0187] In some embodiments, the additional therapeutic agent is a chemotherapeutic agent (also known as an anti-tumor agent or anti-proliferative agent), such as an alkylating agent; an antibiotic; an antimetabolite; an antidote; an interferon; a polyclonal or monoclonal antibody; an EGFR inhibitor; a HER2 inhibitor; a histone deacetylase inhibitor; a hormone; a mitotic inhibitor; an MTOR inhibitor; a multikinase inhibitor; a serine / threonine kinase inhibitor; a tyrosine kinase inhibitor; a VEGF / VEGFR inhibitor; a taxane or taxane derivative, an aromatase inhibitor, an anthracycline, a microtubule-targeted drug, a topoisomerase-poisoning drug, an inhibitor of a molecular target or enzyme (e.g., a kinase or protein methyltransferase), a cytidine analog drug, or any chemotherapeutic agent, immune checkpoint inhibitor, platinum antineoplastic drug, CDK inhibitor, PARP inhibitor, or any anti-tumor or anti-proliferative agent known to those skilled in the art.

[0188] Exemplary alkylating agents suitable for use in accordance with the combination therapy modalities provided herein include, but are not limited to, cyclophosphamide (Cytoxan; Neosar); chlorambucil (Leukeran); melphalan (Alkeran); carmustine (BiCNU); busulfan (Busulfex); lomustine (CeeNU); dacarbazine (DTIC-Dome); oxaliplatin (Eloxatin); carmustine (Gliadel); ifosfamide (Ifex); nitrogen mustard (Mustargen); busulfan (Myleran); carboplatin (Paraplatin); cisplatin (CDDP; Platinol); temozolomide (Temodar); thiotepa (Thioplex); bendamustine (Treanda); or streptozocin (Zanosar).

[0189] Exemplary suitable anthracyclines include, but are not limited to, doxorubicin (Adriamycin); liposomal doxorubicin (Doxil); mitoxantrone (Novantrone); bleomycin (Blenoxane); daunorubicin (Cerubidine); liposomal daunorubicin (DaunoXome); dactinomycin (Cosmegen); epirubicin (Ellence); idarubicin (Idamycin); plicamycin (Mithracin); mitomycin (Mutamycin); pentostatin (Nipent); or valrubicin (Valstar).

[0190] Exemplary antimetabolites include, but are not limited to, fluorouracil (Adrucil); capecitabine (Xeloda); hydroxyurea (Hydrea); mercaptopurine (Purinethol); pemetrexed (Alimta); fludarabine (Fludara); nelarabine (Arranon); cladribine (Cladribine Novaplus); clofarabine (Clolar); cytarabine (Cytosar-U); decitabine (Dacogen); cytarabine liposomal (DepoCyt); hydroxyurea (Droxia); pralatrexate (Folotyn); floxuridine (FUDR); gemcitabine (Gemzar); cladribine (Leustatin); fludarabine (Oforta); methotrexate (MTX; Rheumatrex); methotrexate (Trexall); thioguanine (Tabloid); TS-1 or cytarabine (Tarabine PFS).

[0191] Exemplary antidotes include, but are not limited to, amifostine (Ethyol) or mesna (Mesnex).

[0192] Exemplary interferons include, but are not limited to, interferon alpha-2b (Intron A) or interferon alpha-2a (Roferon-A).

[0193] Exemplary polyclonal or monoclonal antibodies include, but are not limited to, trastuzumab (Herceptin); ofatumumab (Arzerra); bevacizumab (Avastin); rituximab (Retuxin); cetuximab (Erbitux); panitumumab (Vectibix); tositumomab / iodine-131 tositumomab (Bexxar); alemtuzumab (Campass); ibritumomab tiuxetan (zevalin; In-111; Y-90 zevalin); gemtuzumab (Milotuzumab); eculizumab (Soliris) or denosumab.

[0194] Exemplary EGFR inhibitors include, but are not limited to, gefitinib (Iressa); lapatinib (Tykerb); cetuximab (Erbitux); erlotinib (Tarceva); panitumumab (Vectibix); PKI-166; canertinib (CI-1033); matuzumab (EMD 72000), or EKB-569.

[0195] Exemplary HER2 inhibitors include, but are not limited to, trastuzumab (Herceptin); lapatinib (Taricartinib), or AC-480.

[0196] Histone deacetylase inhibitors include, but are not limited to, vorinostat (Zolinza).

[0197] Exemplary hormones include, but are not limited to, tamoxifen (Soltamox; Nolvadex); raloxifene (Evista); megestrol acetate (MegSter); leuprolide (Lupron Depot; Eligard; Viadur); fulvestrant (Farode); letrozole (Fulvovagin); triptorelin (Trelstar LA; Trelstar Depot); exemestane (Aromasin); goserelin (Nurolide); bicalutamide (Casodex); anastrozole (Arimidex); fluoxymesterone (Androxy; Halotestin); medroxyprogesterone (Provera; Depo-Provera); estramustine (Emcyt); flutamide (Eulexin); toremifene (Fareston); degarelix (Firmagon); nilutamide (Nilandron); abarelix (Plenax); or testolactone (Teslac).

[0198] Exemplary mitotic inhibitors include, but are not limited to, paclitaxel (Taxol; Onxol; nab-paclitaxel); docetaxel (Taxotere); vincristine (Oncovin; Vincasar PFS); vinblastine (Velban); etoposide (Toposar; Etopophos; VePesid); teniposide (Vumon); ixabepilone (Ixempra); nocodazole; epothilones; vinorelbine (Navelbine); camptothecin (CPT); irinotecan (Camptosar); topotecan (Hycamtin); amsacrine or lamellaemin D (LAM-D).

[0199] Exemplary MTOR inhibitors include, but are not limited to, everolimus (Canforto) or temsirolimus (Tesirolimus); rapamycin, rifolimus; or AP23573.

[0200] Exemplary multi-kinase inhibitors include, but are not limited to, sorafenib (Nexavar); sunitinib (Sutent); BIBW2992; E7080; Zd6474; PKC-412; motesanib; or AP24534.

[0201] Exemplary serine / threonine kinase inhibitors include, but are not limited to, ruboxistaurin; efavirenz / fasudil hydrochloride; flavopiridol; seliciclib (CYC202; Roscovitine); SNS-032 (BMS-387032); Pkc412; bryostatin; KAI-9803; SF1126; VX-680; Azd1152; Arry-142886 (AZD-6244); SCIO-469; GW681323; CC-401; CEP-1347 or PD 332991.

[0202] Exemplary tyrosine kinase inhibitors include, but are not limited to, erlotinib (Tasai), gefitinib (Iressa), imatinib (Gleevec), sorafenib (Nexavar), sunitinib (Sutent), trastuzumab (Herceptin), bevacizumab (Avastin), rituximab (Retuxin), lapatinib (Tekbo), cetuximab (Erbitux), panitumumab (Vectibix), everolimus (Cancerto), alemtuzumab (Campass), gemtuzumab (Mirostat), temsirolimus ( tadalafil); pazopanib (Votrient); dasatinib (Cedar); nilotinib (Taixian); vatalanib (PTK787; ZK222584); CEP-701; SU5614; MLN518; XL999; VX-322; Azd0530; BMS-354825; SKI-606CP-690; AG-490; WHI-P154; WHI-P131; AC-220; or AMG888.

[0203] Exemplary VEGF / VEGFR inhibitors include, but are not limited to, bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent), ranibizumab, pegaptanib, or vandetanib.

[0204] Exemplary microtubule-targeting drugs include, but are not limited to, paclitaxel, docetaxel, vincristine, vinblastine, nocodazole, epothilone, and navelbine.

[0205] Exemplary topoisomerase toxic drugs include, but are not limited to, teniposide, etoposide, doxorubicin, camptothecin, daunorubicin, dactinomycin, mitoxantrone, amsacrine, epirubicin, and idarubicin.

[0206] Exemplary taxanes or taxane derivatives include, but are not limited to, paclitaxel and docetaxel.

[0207] Exemplary immune checkpoint inhibitors include programmed cell death 1 (PD-1), CD274 molecule (PD-L1), and cytotoxic T lymphocyte-associated protein 4 (CTLA4) inhibitors. Exemplary PD-1 inhibitors include pembrolizumab, nivolumab, and cemiplimab. Exemplary PD-L1 inhibitors include atezolizumab, avelumab, and durvalumab. Exemplary CLTA4 inhibitors include ipilimumab.

[0208] Exemplary platinum-based anti-tumor agents include cisplatin and carboplatin.

[0209] Exemplary cyclin-dependent kinase (CDK) inhibitors include pomacerib, palbociclib, and ribociclib.

[0210] Exemplary poly (ADP-ribose) polymerase (PARP) inhibitors include talazoparib, olaparib, rucaparib, niraparib, and veliparib.

[0211] Exemplary general chemotherapeutic agents, anti-tumor agents, anti-proliferative agents include, but are not limited to, altretinoin (Accutane; Amnesteem; Claravis; Sotret); tretinoin (Vesanoid); azacitidine (Vidaza); bortezomib (Velcade); asparaginase (Elspar); levamisole (Ergamisol); mitotane (Lysodren); procarbazine (Matulane); pegaspargase (Oncaspar); denileukin (Ontak); porfimer (Photofrin); aldesleukin (Proleukin); lenalidomide (Revlimid); bexarotene (Targretin); thalidomide (Thalomid); temsirolimus (Tarisil); arsenic trioxide (Trisenox); verteporfin (Visudyne); mimosine (Leucenol); (1M tegafur-0.4M 5-chloro-2,4-dihydroxypyrimidine-1M potassium oxadiazine), or lovastatin.

[0212] In some embodiments, a combination therapy form is provided, wherein the additional therapeutic agent is a cytokine such as G-CSF (granulocyte colony stimulating factor). On the other hand, the pharmaceutical composition provided herein can be administered in combination with radiotherapy. Radiotherapy can also be administered in combination with the pharmaceutical composition provided herein and another chemotherapeutic agent described herein as a part of multi-agent therapy. On the other hand, the pharmaceutical composition provided herein can be administered in combination with the following standard chemotherapy: such as but not limited to CMF (cyclophosphamide, methotrexate and 5-fluorouracil), CAF (cyclophosphamide, doxorubicin and 5-fluorouracil), AC (doxorubicin and cyclophosphamide), FEC (5-fluorouracil, epirubicin and cyclophosphamide), ACT or ATC (doxorubicin, cyclophosphamide and paclitaxel), rituximab, Xeloda (capecitabine), cisplatin (CDDP), carboplatin, TS-1 (molar ratio of 1: 0.4: 1 of tegafur, gimester and ausstat potassium), camptothecin 11 (CPT-11, irinotecan or Camptosar TM ), CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone or prednisolone), R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone or prednisolone), or CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone).

[0213] In some preferred embodiments, the pharmaceutical compositions provided herein can be administered together with inhibitors of enzymes such as receptor kinases or non-receptor kinases. Receptor kinases or non-receptor kinases are, for example, tyrosine kinases or serine / threonine kinases. Kinase inhibitors described herein are small molecules, polynucleic acids, polypeptides, or antibodies.

[0214] Exemplary kinase inhibitors include, but are not limited to, bevacizumab (targets VEGF), BIBW 2992 (targets EGFR and Erb2), cetuximab / erbitux (targets Erb1), imatinib / Gleevec (targets Bcr-Abl), trastuzumab (targets Erb2), gefitinib / Iresta (targets EGFR), ranibizumab (targets VEGF), pegaptanib (targets VEGF), erlotinib / Tarceva (targets Erb1), nilotinib (targets Bcr-Abl), lapatinib (targets Erb1 and Erb2 / Her2), GW-572016 / lapatinib ditosylate (targets HER2 / Erb2), panitumumab / vicetib (targets EGFR), vandetinib (target RET / VEGFR), E7080 (multiple targets including RET and VEGFR), Herceptin (target HER2 / Erb2), PKI-166 (target EGFR), canertinib / CI-1033 (target EGFR), sunitinib / SU-11464 / sutent (target EGFR and FLT3), matuzumab / Emd7200 (target EGFR), EKB-569 (target EGFR), Zd6474 (target EGFR and VEGFR), PKC-412 (target VEGR and FLT3), vastatin Nibidine / Ptk787 / ZK222584 (target VEGR), CEP-701 (target FLT3), SU5614 (target FLT3), MLN518 (target FLT3), XL999 (target FLT3), VX-322 (target FLT3), Azd0530 (target SRC), BMS-354825 (target SRC), SKI-606 (target SRC), CP-690 (target JAK), AG-490 (target JAK), WHI-P154 (target JAK), WHI-P131 (target JAK), sorafenib / Ne Xavar (targets RAF kinases, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, KIT, FLT-3, and RET), dasatinib / cefadroxil (BCR / ABL and Src), AC-220 (targets Flt3), AC-480 (targets all HER proteins, "panHER"), motassanib diphosphate (targets VEGF1-3, PDGFR, and c-Kit), denosumab (targets RANKL, which inhibits Src), AMG888 (targets HER3), and AP24534 (multiple targets including Flt3).

[0215] In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once a day. In some embodiments, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every two days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every three days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every four days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every five days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every six days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once a week. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every 7-14 days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every 10-20 days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every 5-15 days. In another embodiment, a recombinant fusion protein or a pharmaceutical composition comprising the same polypeptide is administered to a subject once every 15-30 days.

[0216] In one embodiment, the dosage of the recombinant fusion protein of the present invention comprises 0.005 mg / kg to 0.1 mg / kg in an injectable solution. In another embodiment, the dosage comprises 0.005 mg / kg to 0.5 mg / kg of the recombinant fusion protein. In another embodiment, the dosage comprises 0.05 micrograms to 0.1 micrograms of the recombinant fusion protein. In another embodiment, the dosage comprises 0.005 mg / kg to 0.1 mg / kg of the recombinant fusion protein in an injectable solution.

[0217] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dosage ranging from 0.0001 mg to 0.6 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dosage ranging from 0.001 mg to 0.005 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dosage ranging from 0.005 mg to 0.01 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dosage ranging from 0.01 mg to 0.3 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dosage ranging from 0.2 mg to 0.6 mg.

[0218] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 1-100mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 10-80mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 20-60mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 10-50mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 40-80mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 10-30mcg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose in the range of 30-60mcg / kg.

[0219] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 100mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 50mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 25mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 10mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 5mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 1mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 0.1mcg / kg to 0.1mg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at a dose ranging from 10 mg / kg to 60 mg / kg.

[0220] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg, about 60 mg / kg or about 70 mg / kg.

[0221] In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 0.2 mg to 2 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 2 mg to 6 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 4 mg to 10 mg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 5 mg to 15 mg.

[0222] In one embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 10 μg / kg to 1000 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 25 μg / kg to 600 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose ranging from 50 μg / kg to 400 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 25 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 50 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 100 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 200 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 300 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 400 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 500 μg / kg. In another embodiment, the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to a subject at a dose of about 600 μg / kg.

[0223] In one embodiment, a single dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject. In another embodiment, a total of two doses are administered to the subject. In another embodiment, a total of two or more doses are administered to the subject.

[0224] In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once a day. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once every two days. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once every two days or more. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject every two days, every two weeks, or every three weeks. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once a week. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once every two weeks. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once every three weeks. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once every three weeks or more weeks. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice a week or more. In another embodiment, a dose of recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice a month or more. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice or more a year. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice or more every two years. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject twice or more every two or more years.

[0225] In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 36 hours. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 48 hours. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 60 hours. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 72 hours. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 84 hours. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 96 hours. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 5 days. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 6 days. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 7 days. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 8-10 days. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 10-12 days. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 12-15 days. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 15-25 days. In another embodiment, a dose of the recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 20-30 days.

[0226] In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered to the subject at least once every month. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 2 months. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 3 months. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 4 months. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 5 months. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 6 months. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered at least once every 6-12 months. In another embodiment, a dose of a recombinant fusion protein or a pharmaceutical composition comprising the same is administered quarterly. In another embodiment, the dose is administered daily, weekly, biweekly, monthly or annually. In another embodiment, the dose is administered once, twice or twice or more daily, weekly, monthly or annually. In another embodiment, the dose is administered every two years, every three years, every four years or every at least five years.

[0227] In one embodiment, repeated administrations (doses) of the compositions of the invention may be performed immediately after a first course of treatment or after intervals of days, weeks, or years to achieve the desired effect (e.g., prevention or treatment of a cardiovascular disease or condition, or a disease or condition associated with the CNS) as further provided herein.

[0228] In one embodiment, the pharmaceutical composition is administered by intravenous, intraarterial, subcutaneous or intramuscular injection of a liquid formulation. In another embodiment, the liquid formulation comprises a solution, a suspension, a dispersion, an emulsion, an oil, etc. In one embodiment, the pharmaceutical composition is administered intravenously, and thus the pharmaceutical composition is formulated into a form suitable for intravenous administration. In another embodiment, the pharmaceutical composition is administered intraarterially, and thus the pharmaceutical composition is formulated into a form suitable for intraarterial administration.

[0229] In some embodiments, compositions for use in the methods disclosed herein include solutions or emulsions, which in some embodiments are aqueous solutions or emulsions comprising a safe and effective amount of a compound disclosed herein and optionally other compounds intended for intravenous or subcutaneous administration.

[0230] In some embodiments, the various components of the composition are pre-measured and / or pre-packaged and / or ready to use without additional measurement, etc. The present invention also optionally includes a kit for performing / using the method and / or composition of the present invention. Specifically, these kits optionally include, for example, appropriate recombinant fusion proteins (and optional mixtures of many such proteins for performing synergistic therapy, see above), and one or more optionally appropriate disease-related antigens). In addition, such kits may also include appropriate excipients (e.g., pharmaceutically acceptable excipients) for performing therapeutic and / or preventive treatments of the present invention. Such kits optionally contain additional components for assembling and / or using the composition of the present invention (including but not limited to diluents, etc.).

[0231] The compositions described herein are optionally packaged to contain all (or substantially all) of the necessary components for performing the methods of the invention or using the compositions of the invention (optionally containing, for example, written instructions for use of the methods / compositions of the invention). For example, the kits may optionally contain components such as buffers, reagents, serum proteins, antibodies, substrates, etc. In the case of prepackaged reagents, the kits optionally contain pre-measured or pre-dosed quantities ready for incorporation into the method without measurement, for example, pre-measured liquid viscosities, or pre-weighed or pre-measured solid reagents that can be easily reconstituted by the end user of the kit.

[0232] Such kits also typically include appropriate instructions for performing the methods of the present invention and / or using the compositions of the present invention. In some embodiments, the components of the kit / package are provided in a stable form to prevent degradation or other losses during extended storage, such as to prevent leakage. Many stabilization processes / agents are widely used for reagents to be stored, such as those containing chemical stabilizers (i.e., enzyme inhibitors, bactericides / bacteriostats, anticoagulants), etc. The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be changed to obtain the amount, composition, and mode of administration of the active ingredient that effectively achieves the desired therapeutic response for a specific subject, without toxicity to the subject. The selected dosage level will depend on various pharmacokinetic factors, including the activity of the specific composition of the present invention used; route of administration; time of administration; excretion rate of the specific compound used; duration of treatment; other drugs, compounds, and / or materials used in combination with the specific compound used; age, sex, weight, condition, general health, and previous medical history of the subject being treated; and similar factors well known in the medical field.

[0233] The composition must be sterile and mobile so that the composition can be delivered by a syringe. In addition to water, the carrier is preferably an isotonic buffered saline solution. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the required particle size in the case of a dispersion, and by using a surfactant. In many cases, preferably, an isotonic agent, for example a sugar, a polyol such as mannitol or sorbitol, and sodium chloride are included in the composition.

[0234] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of active ingredient, composition and mode of administration that is effective to achieve the desired therapeutic response for a particular subject, without being toxic to the subject. The selected dosage level will depend on various pharmacokinetic factors, including the activity of the particular composition of the present invention employed; the route of administration; the time of administration; the excretion rate of the particular compound employed; the duration of treatment; other drugs, compounds and / or materials used in combination with the particular compound employed; the age, sex, weight, condition, general health and previous medical history of the subject being treated; and similar factors well known in the medical field.

[0235] Although several inventive embodiments have been described and shown herein, it will be readily apparent to those of ordinary skill in the art that various other devices and / or structures for performing the functions described herein and / or obtaining these results and / or one or more of these advantages will be contemplated, and each of such variations and / or modifications is considered to be within the scope of the inventive embodiments described herein. More generally, it will be readily appreciated by those of skill in the art that all parameters, dimensions, materials, and configurations described herein are meant to be exemplary, and that actual parameters, dimensions, materials, and / or configurations will depend on one or more specific applications for which the teachings of the present invention are used. Using only routine experiments, those of skill in the art will recognize or be able to confirm many equivalents of the specific inventive embodiments described herein. Therefore, it should be understood that the foregoing embodiments are introduced only by way of example, and within the scope of the appended claims and their equivalents, embodiments of the present invention may be practiced in a manner different from that specifically described and required. The inventive embodiments of the present disclosure relate to each individual feature, system, article, material, kit, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, kits and / or methods is included within the inventive scope of the present disclosure if such features, systems, articles, materials, kits and / or methods are not mutually inconsistent.

[0236] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and / or ordinary meanings of the defined terms.

[0237] All references, patents, and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which they are respectively cited, which in some cases may be the entirety of the document.

[0238] As used herein in the specification, the indefinite articles “a” and “an” should be understood to mean “at least one” unless explicitly indicated to the contrary.

[0239] As used herein in the specification, the phrase "and / or" should be understood to mean "either one or both" of the elements so united, that is, the elements exist together in some cases and separately in other cases. Multiple elements listed with "and / or" should be interpreted in the same way, that is, "one or more" of the elements so connected. In addition to the elements specifically indicated by the "and / or" clause, other elements may optionally be present, whether related or unrelated to those elements specifically indicated. Therefore, as a non-limiting example, when used in conjunction with open languages ​​such as "including", references to "A and / or B" may: in one embodiment, refer only to A (optionally including elements 5 other than B); in another embodiment, refer only to B (optionally including elements other than A); in yet another embodiment, refer to both A and B (optionally including other elements); etc.

[0240] As used in this specification and claims, the phrase "at least one" with respect to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including at least one of each element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows that elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers may optionally be present, whether or not related to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or equivalently, "at least one of A or B", or equivalently "at least one of A and / or B") may refer to at least one, optionally including more than one A, without the presence of B (and optionally including elements other than B) in one embodiment; may refer to at least one, optionally including more than one B, without the presence of A (and optionally including elements other than A) in another embodiment; may refer to at least one, optionally including more than one B, without the presence of A (and optionally including elements other than A) in yet another embodiment; may refer to at least one, optionally including more than one A, and at least one, optionally including more than one B (and optionally including other elements); etc.

[0241] The present invention further provides a kit for preventing, treating or delaying a cardiovascular disease or condition in a human, wherein the kit comprises one or more doses of a pharmaceutical composition comprising a recombinant fusion protein disclosed herein for preventing, treating or delaying a cardiovascular disease or condition, and instructions for how to use the pharmaceutical preparation or composition.

[0242] The present invention further provides a kit for preventing, treating or delaying a CNS-related disease or condition in a human, wherein the kit comprises one or more doses of a pharmaceutical composition comprising a recombinant fusion protein disclosed herein for preventing, treating or delaying a cardiovascular disease or condition, and instructions for how to use the pharmaceutical preparation or composition.

[0243] The present invention further provides a kit for preventing, treating or delaying heart failure with preserved ejection fraction in humans, wherein the kit comprises one or more doses of a pharmaceutical composition comprising a recombinant fusion protein disclosed herein for preventing, treating or delaying heart failure with preserved ejection fraction, and instructions for how to use the pharmaceutical preparation or pharmaceutical composition.

[0244] The following examples are described in order to more fully demonstrate the preferred embodiments of the present invention. However, the examples should in no way be interpreted as limiting the broad scope of the present invention.

[0245] Examples

[0246] Example 1 - Cloning and construction of expression plasmid

[0247] The DNA sequences encoding the heavy chain (named NPCFA and NPCF with or without Fc mutations, respectively) and light chain (named PAL) of the recombinant fusion protein were synthesized by GENEWIZ Biotechnology Co., Ltd. (Suzhou, China). The expression vector pCHOGUN was obtained from Horizon Discovery (Cambridge, UK) under a license agreement. The expression plasmids were constructed as shown in Figure 1 .In short, pCHOGUN vector is linearized by restriction enzyme BfuAI, and after double restriction enzyme digestion by NcoI and AscI, gene inserts such as NPCF, NPCFA and PAL are purified. Linearized pCHOGUN / BfuAI and purified gene inserts are connected according to standard protocols, and then transformed into Escherichia coli DH5α competent cells. DH5α cells are plated and incubated overnight at 37 ℃. Separate and confirm plasmid pCHOGUN-NPCF, pCHOGUN-NPCFA and pCHOGUN-PAL by restriction enzyme digestion or PCR. The plasmid (pCHOGUN-NPCF or pCHOGUN-NPCFA) containing the heavy chain is digested with restriction enzyme BspEI and PciI, and the plasmid (pCHOGUN-PAL) containing the light chain is inserted is digested with restriction enzyme NgoMIV and PciI. After restriction enzyme digestion, the fragments with heavy chain insertion or light chain insertion were purified, ligated, and then transformed into DH5α cells. Plasmid constructs (pCHOGUN-NPCF+PAL or pCHOGUN-NPCFA+PAL) containing both heavy chain insertion and light chain insertion were identified and confirmed by restriction enzyme digestion and DNA sequencing.

[0248] Example 2 - Antibody Production, Purification and Characterization

[0249] HD-BIOP3 was obtained from Horizon Discovery (Cambridge, UK) under a license agreement: glutamine synthetase null (GS) derived from CHO K1 cells - / - ) cell line. Plasmid DNA was isolated using a commercially available Qiagen plasmid kit. Plasmid DNA was transfected into HD-BIOP3 cells using a commercially available electroporation system from Lonza. Transfected cells were plated in 96-well plates, and standard procedures were used to select transfected cells through pools. Cells from the selected pools were cultured in 125 mL shake flasks for 10-14 days, and culture medium was collected for antibody purification. Antibody proteins were purified by protein A affinity chromatography, followed by size exclusion chromatography, and then analyzed by SDS-PAGE and Western blot according to standard protocols.

[0250] Figure 2A Schematic structures of recombinant fusion proteins disclosed herein are shown. Figure 2B Representative data generated by SDS-PAGE analysis are shown. Figure 2C and 2D Shown are the results of Western blots detected by a primary antibody specific for a 61-amino acid active fragment of NRG-1 including the HER3 / 4 binding domain ("NRG-1", R&D Systems, Minneapolis, MN) or IgG, respectively.

[0251] Example 3 - Molecular integrity assessed by SPR-based binding assay

[0252] The molecular structural integrity of the recombinant fusion protein disclosed herein was assessed by evaluating the ability to bind to HER3 protein and anti-NRG-1 antibody simultaneously. The His-tagged HER3 recombinant protein (Sino Biologics, Beijing, China) was captured on a sensor chip fixed with anti-His antibody (Thermo Fisher, Waltham, MA) (step 1) and then injected with a sample (comprising the recombinant fusion protein disclosed herein, the recombinant fusion protein without Fc mutation disclosed herein, anti-HER3 mAb (step 2), and anti-NRG-1 antibody (R&D Systems, Minneapolis, MN) (step 3). Biological, Beijing, China)). In step 1, the His-HER3 connection can be visualized on the sensor chip by increasing the signal on all 6 channels. Both the recombinant fusion protein disclosed herein and the recombinant fusion protein disclosed herein without Fc mutation produced a significant response by binding to HER3 in step 2 and by binding to the injected anti-NRG-1 antibody (Ch1, 3) in step 3, indicating the presence of HER3 binding epitopes and NRG-1 on the recombinant fusion protein disclosed herein. In contrast, the anti-HER3 mAb only binds to His-HER3 in step 2, but not to the anti-NRG-1 antibody and buffer (step 3) (Ch4, 5), thereby verifying the absence of NRG-1 binding activity of the anti-HER3 mAb molecule. Buffer was injected in steps 2 and 3 as a blank control. Therefore, both the HER3 binding epitope and NRG-1 are present in the recombinant fusion protein of the present invention.

[0253] Figure 3 The binding sensorgram and sample injection sequence are shown in .

[0254] Example 4 - Effects on proliferation of tumor cell lines in vitro

[0255] Depending on the growth kinetics of each cell line, tumor cells were seeded into 96-well plates at 2,500-20,000 cells per well. Cells were then treated with a stepwise 1:4 serial dilution series of recombinant fusion proteins, antibodies, or control proteins disclosed herein for 5 days. Cell viability was assessed using a cell counting kit-8 from Dojindo Molecular Technologies (Kumamoto, Japan) according to the manufacturer's instructions. Data were analyzed using GraphPadPrism software and expressed as growth rates relative to untreated controls.

[0256] Figure 4 contains representative graphs showing the mean relative growth rate ± SEM (n=3) of the following different cancer cell lines: (A) NCI-N87, stomach; (B) MCF-7, breast; (C) RT-112, bladder; and (D) T47D, breast. Compared with the control NRG-1 and GP120mAb / NRG-1 fusion proteins, the recombinant fusion proteins disclosed herein exhibit significantly lower activity in promoting cancer cell proliferation.

[0257] Example 5 - Activation of the PI3K / AKT signaling pathway in human cardiomyocytes

[0258] Human cardiomyocytes from Cellular Dynamics (Madison, WI) were seeded in 0.1% gelatin-coated 96-well plates and recovered in plate culture medium (Cellular Dynamics) for 4 hours. The cells were then cultured in maintenance medium (Cellular Dynamics) for 96 hours before being used in experiments. In order to examine the ability of the recombinant fusion protein of the present invention to activate the HER2:HER4 signaling pathway in cardiomyocytes, the cells were first starved for 4 hours in serum-free medium, and then treated with recombinant fusion protein or control agent (NRG-1, GP120mAb / NRG-1, anti-HER3mAb or GP120mAb) in a stepwise 1:4 serial dilution series for 15 minutes. At the end of the treatment, the cells were lysed and analyzed for AKT phosphorylation using Abcam's phospho-AKT / total AKT ELISA kit (Cambridge, MA) according to the manufacturer's instructions. Data were analyzed with GraphPad Prism software and expressed as the ratio of phospho-AKT to total AKT relative to untreated controls.

[0259] For western blot analysis, cells were seeded in 6-well plates and treated with a single concentration of 16 nM using the recombinant fusion protein of the present invention or a control agent. At the end of the treatment, cells were lysed in RIPA lysis buffer containing protease and phosphatase inhibitors. SDS-PAGE and western blot were performed according to standard protocols. Total AKT and phospho-AKT were blotted with AKT rabbit antibody and p-AKT (S473) rabbit antibody (Cell Signaling, Denver, MA; Danvers, MA) respectively.

[0260] Figure 5 shows AKT phosphorylation in response to stimulation in human cardiomyocytes.The results indicate that the recombinant fusion proteins disclosed herein can activate the HER2:HER4 signaling pathway in cardiomyocytes with comparable potency to NRG-1.

[0261] Example 6: Induction of HER2:HER3 dimerization and HER2:HER4 dimerization

[0262] The PathHunter dimerization assay, developed by Eurofins DiscoverX (Fremont, CA), detects ligand-induced dimerization of the two subunits of a receptor-dimer pair. Fig. 6A The assay principle is demonstrated in . The β-gal enzyme is split into two fragments: ProLink (PK) and enzyme receptor (EA). Cells have been engineered to co-express target protein 1 fused to the enzyme donor PK and target protein 2 fused to the enzyme receptor EA. Binding of a ligand to one target protein induces the interaction of the ligand with the other target protein, forcing the complementation of the two enzyme fragments and allowing the enzyme reaction to release a chemiluminescent signal that is detected in the form of relative fluorescence units or RFU.

[0263] PathHunter U2OS ErbB2 / ErbB4 dimerization cell line and ErbB2 / ErbB3 dimerization cell line were obtained from Eurofins DiscoverX. Cells were seeded at 4,000 cells / well in 384-well plates and incubated at 37°C / 5% CO 2 The cells were incubated overnight at 4 °C. Test agents were prepared in a stepwise 1:4 serial dilution series starting from 28.8 nM and then added to cells in 384-well plates. After 4 hours of incubation, cells were subjected to a receptor dimerization assay according to the manufacturer's instructions. Data were analyzed using GraphPad Prism software and are presented as mean RFU ± SEM (n = 3).

[0264] like Figure 6B and 6C As shown, the recombinant fusion protein disclosed herein can induce HER2 / HER4 dimerization with an efficacy comparable to NRG-1; however, the ability of the recombinant fusion protein to induce HER2 / HER3 dimerization is much weaker. As negative controls for the study, the isotype control antibody GP120mAb and anti-HER3mAb did not induce receptor dimerization.

[0265] Having described the embodiments of the present invention with reference to the accompanying drawings, it should be understood that the present invention is not limited to the precise embodiments and that various changes and modifications may be implemented therein by those skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

[0266] Example 7: In vivo efficacy of recombinant fusion protein in a rat model of systolic heart failure

[0267] To evaluate the ability of recombinant fusion proteins to regenerate cardiac function in disease models, a Sprague Dawley rat model of myocardial infarction and systolic heart failure was used. To establish the disease model, the left anterior descending coronary artery (LAD) was ligated 3-4 mm below the left atrial appendage using a 6-0 silk suture during surgery. Four weeks after ligation, the ejection fraction (EF) was recorded by M-mode echocardiography (ECG) Doppler ultrasound before surgery to measure cardiac function against baseline EF. A threshold of a minimum decrease in EF of 30% was used for inclusion in subsequent studies. Sham control animals underwent the same surgery without LAD ligation.

[0268] After establishing the disease model, the animals were divided into five groups of eleven rats each, with the sixth group containing an additional ten sham-operated rats. The study was designed to allow each group to receive tail vein injections twice a week for four weeks, or a total of eight injections. Both the sham-operated group and the negative control of the vehicle group received normal saline, three groups received 1 mg / kg, 3 mg / kg or 10 mg / kg of the recombinant fusion protein, and the last group received a positive control of GP120mAb / NRG-1 fusion protein (10 mg / kg).

[0269] Because of the weight loss observed during the study, treatment was discontinued before the recombinant fusion protein groups received a full sequence of eight injections at 3 mg / kg and 10 mg / kg, where those groups received only six and three injections, respectively. All other groups received a full set of eight injections.

[0270] Four weeks after the first treatment, EF was measured again by M-mode ECG. Figure 8 As shown, the recombinant fusion protein significantly increased EF in all three dose groups relative to baseline. Specifically, increases of 14.7% (P<0.001), 26.9% (P<0.001), and 36.6% (P<0.001) were observed in the 1 mg / kg, 3 mg / kg, and 10 mg / kg groups, respectively. At the matched time points, the GP120mAb / NRG-1 positive control increased EF by 28.8% (P<0.001). Saline had no effect in either the sham or vehicle control groups.

[0271] After collecting ECG values ​​28 days after treatment, mice were euthanized and heart tissues near the surgical site were collected, fixed in 4% formaldehyde and embedded in paraffin. 5 μm thick paraffin sections of heart tissues were stained with hematoxylin and eosin dyes and observed for histopathological changes under an optical microscope. Fig. 9As shown, in the sham group, the cardiomyocytes were arranged in an orderly manner, and the cytoplasm and myocardial fibers were uniformly stained. Inflammatory cell infiltration was not observed in the interstitial space, and myocardial necrosis was not found. In contrast, in the vehicle control group, the cardiomyocytes in the marginal zone of myocardial infarction showed widening of the gaps; the nuclei were compressed and fragmented, and the myocardial fiber arrangement lost its orderly structure; the cell size increased, and interstitial edema was noted. Treatment with the recombinant fusion protein partially alleviated the pathological changes in the myocardial infarction area, including a significant reduction in necrotic cells, a narrowing of the interstitial space between cardiomyocytes, and the restoration of myocardial fiber arrangement toward normal structure.

[0272] Example 8: Recombinant fusion protein attenuates tumor growth in a subcutaneous FaDu cancer xenograft model in NOD / SCID mice

[0273] In order to evaluate the potential risk of recombinant fusion protein in promoting tumor growth, in vivo studies were performed in FaDu cancer xenograft models. According to institutional guidelines, NOD / SCID mice (Beijing AK Bio-Technology Co. Ltd.) were maintained in the SPF facilities of the CrownBio international R&D center (Beijing, China) in China. All experiments were performed according to the requirements of the Laboratory Animal Care Assessment and Accreditation Committee (AAALAC) and with the permission of the CrownBio IACUC Committee.

[0274] Female NOD / SCID mice aged 7-10 weeks were subcutaneously inoculated in the right flank with FaDu tumor cells (3 × 10 6 ). When the tumor reaches about 150mm 3 At 1 , mice were randomized and divided into 6 study groups with 8 animals in each group. Test samples were administered intravenously via tail vein injection twice a week for three consecutive weeks, for a total of 6 treatments. Tumor growth was monitored by caliper measurement. The study was terminated 21 days after treatment.

[0275] Fig.10Tumor growth in response to different treatments is summarized. 10 mg / kg of anti-HER3 mAb showed significant antitumor activity, with a tumor growth inhibition (TGI) of 93.5% at the end of the study (p<0.001 relative to the vehicle group). At the end of the study, the recombinant fusion protein also exhibited a statistically significant TGI: 19.2% at a dose of 1 mg / kg (p=0.048 relative to the vehicle group) and 56.2% at a dose of 10 mg / kg (p<0.001 relative to the vehicle group). The control molecule GP120mAb / NRG-1 fusion protein showed no antitumor activity at high or low doses. No animal deaths occurred during the study. Tumor-bearing mice tolerated all test agents well. No significant weight loss was observed in any experimental group ( Fig.11 ). These data show that under conditions of active tumor growth in vivo, the recombinant fusion protein exhibits tumor growth inhibition in a dose-dependent manner and indicate that the risk of the recombinant fusion protein enhancing or accelerating tumor growth in vivo is lower than that of the native NRG-1 protein.

[0276] Example 9: No significant gastrointestinal toxicity was observed in cynomolgus monkeys administered the recombinant fusion protein

[0277] It was previously reported that in a Phase 1 clinical study (NCT01258387) in which subjects received either placebo or a single dose of cimaglermin (full-length recombinant NRG-1β3), nausea and diarrhea were the second and fourth most common treatment-emergent adverse events, occurring in 40% and 27% of the combined high-dose cohort, respectively (Lenihan et al. J Am Coll Cardiol Basic Trans Science 2016;1(7):576-86). Similarly, in a Phase 2 study of a recombinant NRG-1 peptide fragment (neucardin), nausea was the most commonly observed treatment-emergent adverse event, seen in 20% of study subjects (Jabbour et al. European Journal of Heart Failure (2011) 13:83–92). Finally, in a second phase 2 study of necardin (ChiCTR-TRC-00000414), published results showed that 48.4% of adverse events were observed to be gastrointestinal in nature, the most common type of adverse event observed in this study, and were related to dose level (Gao et al. J Am Coll Cardiol 2010;55:1907–14).

[0278] Two studies were conducted to evaluate the safety and tolerability of the recombinant fusion protein in cynomolgus monkeys (Macaca fascicularis): a single-dose non-GLP (good laboratory practice) study and a repeated-dose GLP study. Gastrointestinal toxicity was closely monitored. In the single-dose study, the safety and tolerability of the recombinant fusion protein were evaluated at dose levels of 10 mg / kg, 30 mg / kg and 60 mg / kg compared to vehicle controls, with one male animal and one female animal included in each group. In this single-dose study, there was no test agent-related effect on body weight or qualitative food assessment during the two-week evaluation period after the entire treatment, and no vomiting or diarrhea was observed. In a repeated dose GLP study, compared to vehicle control, once a week for four consecutive weeks at 3mg / kg, 10mg / kg and 30mg / kg dose levels were administered, the safety and tolerability of the recombinant fusion protein was evaluated, wherein three males and three females were included in each group during the main 28-day study period, and two additional males and two females were included in 30mg / kg, and the vehicle control group was evaluated after a subsequent 28-day recovery period. No test agent-related effects on food consumption were observed in this repeated dose study. Although test agent-related vomiting was observed in this repeated dose study, the clinical observation of vomiting was associated only with injection reactions, and vomiting was observed only in one animal (17%) in the 10mg / kg group and in two animals (20%) in the 30mg / kg group, and the vomiting was transient in nature. Diarrhea was observed only in the vehicle control group and the 30 mg / kg recombinant fusion protein group, in one animal (10%) and three animals (30%), respectively, and was considered normal for this type of procedure and unrelated to the recombinant fusion protein. Finally, in this repeated dose study, mean body weight was reduced by >10% relative to baseline only at the 10 mg / kg and 30 mg / kg dose levels and only after the fourth dose in the 10 mg / kg group and the third and fourth doses in the 30 mg / kg group. In summary, treatment with the recombinant fusion protein did not result in any clinically significant findings related to food intake, vomiting or diarrhea, except during acute infusion reactions, and gastrointestinal findings had no effect on the determination of non-adverse event levels in either study. These results indicate that the design of the recombinant fusion protein mitigates the adverse effects of the NRG-1 recombinant protein on the gastrointestinal tract.

[0279] After administering a single dose of 60 mg / kg of the recombinant fusion protein at different time points, blood samples (~1 ml) were collected from cynomolgus monkeys, and serum was extracted and stored at -80 ° C until testing. According to standard procedures, the concentration of the recombinant fusion protein in the serum samples was determined by capture ELISA. In brief, 96-well plates were coated with recombinant human HER3 protein (R&D Systems), blocked with BSA and incubated with test samples. After multiple washings, the plates were incubated with anti-human IgG Fc antibodies combined with HRP, and then detected with TMB substrate. Fig.12 It was shown that the pharmacokinetic profile of the recombinant fusion protein was similar to that of an IgG antibody.

[0280] Example 10: Summary of kinetic constants for Fc receptor binding

[0281] The binding affinity between recombinant anti-HER3mAb / NRG-1 fusion protein and Fc receptor was measured using label-free SPR technology. A total of six Fc receptors (each fused to a His tag) were analyzed for recombinant fusion proteins, recombinant fusion proteins without Fc mutations, and anti-HER3 antibodies, including FcγRI (Abcam), FcγRIIa, FcγRIIb, FcγRIIIa (158F), FcγRIIIa (158V), and C1q (Sino-Biotech Co., Ltd.). All Fc receptors and test samples were purified by affinity chromatography. All experiments were performed on a Biacore 8K system (GE Healthcare) using HBS-EP+ (10mM HEPES, 150mMNaCl, 3mM EDTA, and 0.05% v / v surfactant P20) as running buffer. Specifically, anti-His antibodies were coupled to the active flow cell and reference flow cell of a CM5 sensor chip by amino coupling. Purified His-tagged Fc receptors were captured on the active flow cell of each individual channel by binding to an immobilized anti-His antibody. The capture level of each Fc receptor was maintained between 80-120RU. For kinetic analysis, the recombinant fusion protein and all other samples were serially diluted to a total of 6 concentrations ranging from 0.3nM to 30nM and the serial dilutions were injected sequentially through two flow cells in each channel. Multiple analyses were completed in the same run by injecting samples simultaneously on multiple channels.

[0282] The resulting sensorgrams were fitted with a two-state binding model using Biacore 8K evaluation software to extract kinetic constants. Table 1 below summarizes the equilibrium dissociation rates (KD) for all analyses. The kinetic-derived KD values ​​for the recombinant fusion proteins bound to FcγRI, FcγRIIa, and FcγRIIb were more than 10 times greater than the values ​​for the recombinant fusion proteins and anti-HER3 antibodies without Fc mutations, indicating that specific mutations in the Fc region of the recombinant fusion protein made the affinity much lower. In the case of FcγRIIIa (158F) and FcγRIIIa (158V), the Fc mutation reduced the binding affinity of the recombinant fusion protein by 2 to 3 times. For all samples, the binding to C1q was too weak to be detected.

[0283] In order to confirm that the recombinant fusion protein has limited Fc effector function, ADCC was checked using the antibody-dependent cellular toxicity (ADCC) reporter gene bioassay from Promega (Madison, Wisconsin). The assay uses the engineered Jurkat cell line as effector cell, which stably expresses FcγRIIIa (V158) receptors and the NFAT response element driving firefly luciferase expression. Rituximab shows strong ADCC activity to CD20 positive Raji cells as the positive control of the assay; however, the recombinant fusion protein does not have detectable ADCC (data not shown) for HER3 positive target cells (MCF7 or BT474).

[0284] Table 1: Summary of kinetic constants for Fc receptor binding

[0285]

[0286] *

Claims

1. A recombinant fusion protein comprising an active fragment of the cardioprotective protein neuregulin-1 (NRG-1), the fragment being fused to a monospecific ErbB3 (HER3) monoclonal antibody (mAb), the mAb comprising a heavy chain and a light chain comprising an Fc domain, wherein the NRG-1 active fragment binds to ErbB4 (HER4) and induces signal transduction through the ErbB4 (HER4), and the mAb inhibits NRG-1 signal transduction through ErbB3 (HER3). 2 . The recombinant fusion protein according to claim 1 , wherein the NRG-1 active fragment comprises the NRG-1 β2a isoform.

3. The recombinant fusion protein according to claim 1 or 2, wherein the NRG-1 active fragment is fused to the C-terminus of the antibody heavy chain via its N-terminal amino acid using a linker.

4. The recombinant fusion protein according to claim 3, wherein the linker comprises at least one copy of the Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly-Gly-Gly-Ser linker shown in SEQ ID NO:

5.

5. The recombinant fusion protein according to any one of claims 1 to 4, wherein the C-terminus of the antibody heavy chain comprises the Fc domain of the antibody.

6. The recombinant fusion protein according to any one of claims 1 to 5, wherein the monoclonal antibody is glycosylated. The recombinant fusion protein according to claim 6 , wherein the glycosylation is N-glycosylation or O-glycosylation.

8. The recombinant fusion protein according to any one of claims 1 to 7, wherein the NRG-1 fragment comprises the amino acid sequence of SEQ ID NO:

4.

9. The recombinant fusion protein according to any one of claims 1 to 8, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:

2.

10. The recombinant fusion protein according to any one of claims 1 to 9, wherein the light chain comprises the amino acid sequence of SEQ ID NO:

3.

11. The recombinant fusion protein of any one of claims 1-8, wherein the mAb comprises a substitution mutation in at least one of amino acids 234, 239 and 434 of SEQ ID NO:

2. 12 . The recombinant fusion protein of claim 11 , wherein the at least one substitution mutation comprises an L234F mutation, an S239A mutation, an N434A mutation, or a combination thereof.

13. The recombinant fusion protein according to any one of claims 1 to 8, wherein the recombinant fusion protein comprises the amino acid sequences of SEQ ID NO: 3 and SEQ ID NO:

14.

14. The recombinant fusion protein of any one of claims 1-13, wherein the recombinant fusion protein attenuates the proliferation of tumor or cancer cells relative to recombinant NRG-1.

15. The recombinant fusion protein according to any one of claims 1 to 14, wherein the recombinant fusion protein promotes cardiomyocyte proliferation, differentiation and survival.

16. The recombinant fusion protein according to any one of claims 1 to 15, wherein the recombinant fusion protein promotes proliferation, differentiation and survival of cardiac tissue.

17. The recombinant fusion protein according to any one of claims 1 to 16, wherein the ability of the recombinant fusion protein to induce antibody-dependent cellular cytotoxicity (ADCC) is reduced.

18. The recombinant fusion protein of any one of claims 1-17, wherein relative to the signal induction potential of recombinant NRG-1, the recombinant fusion protein promotes HER2 / 4 signaling over HER2 / 3 signaling.

19. A recombinant nucleic acid molecule encoding the recombinant fusion protein according to any one of claims 1 to 18.

20. The recombinant nucleic acid molecule of claim 19, wherein the heavy chain of the mAb is encoded by a sequence comprising SEQ ID NO:6 or SEQ ID NO:

7.

21. The recombinant nucleic acid molecule of claim 19 or 20, wherein the light chain of the mAb is encoded by a sequence comprising SEQ ID NO:

8.

22. A recombinant vector comprising the nucleic acid molecule according to any one of claims 19-21. A recombinant cell comprising the recombinant vector according to claim 22 .

24. A pharmaceutical composition comprising the recombinant fusion protein according to any one of claims 1-18.

25. A kit comprising an effective amount of the recombinant fusion protein according to any one of claims 1 to 18 or the pharmaceutical composition according to claim 24.

26. Use of the recombinant fusion protein according to any one of claims 1 to 18, or the pharmaceutical composition according to claim 24, or the kit according to claim 25 in the preparation of a medicament for treating, preventing, inhibiting, preventing or delaying the onset of cardiovascular disease in a subject in need thereof.

27. The use of claim 26, wherein the treatment reduces signs or symptoms of the cardiovascular disease in the subject.

28. The use according to claim 26 or 27, comprising administering to the subject a drug at 0.1 mcg / kg to 5 mg / kg of the recombinant fusion protein.

29. Use according to any one of claims 26-28, wherein the cardiovascular disease is systolic heart failure.

30. The use according to any one of claims 26-28, wherein the cardiovascular disease is chronic heart failure / congestive heart failure (CHF), acute heart failure / myocardial infarction (MI), left ventricular systolic dysfunction, reperfusion injury associated with MI, chemotherapy-induced cardiotoxicity (adult or pediatric), radiation-induced cardiotoxicity, adjunct to surgical intervention for congenital heart disease in children.

31. The use according to claim 30, wherein the chemotherapy-induced cardiotoxicity is caused by the subject receiving an anthracycline, an alkylating agent, an anti-microtubule agent or an antimetabolite agent as chemotherapy.

32. The use according to any one of claims 26-28, wherein the cardiovascular disease comprises cardiotoxicity caused by cancer therapy received by the subject.

33. The use according to claim 32, wherein the cancer therapy is a HER-2 targeted therapy, preferably the HER-2 targeted therapy comprises the use of trastuzumab, ado-trastuzumab, emtansine, lapatinib, neratinib, pertuzumab, any anti-HER2 antibody, any anti-HER2 agent or a combination thereof.

34. A method for producing a recombinant fusion protein according to any one of claims 1 to 18, wherein the method include: (a) transforming a eukaryotic host cell with at least a first vector comprising a sequence encoding the light chain of the monoclonal antibody backbone and a sequence encoding the heavy chain of the monoclonal antibody backbone fused via its C-terminus to the N-terminus of the NRG-1 fragment; (b) culturing the eukaryotic host cell under conditions sufficient to express the recombinant fusion protein; and (c) purifying the recombinant fusion protein.

35. The method of claim 34, wherein the eukaryotic host cell comprises a CHO cell, preferably the CHO cell comprises a CHO-K1 cell.